BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12:1179-1187. [PMID: 16682560 DOI: 10.1261/rna.25706] [Cited by in Crossref: 607] [Cited by in F6Publishing: 586] [Article Influence: 37.9] [Reference Citation Analysis]
Number Citing Articles
1 Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, Kamens J, Thompson JD, Nochur S, Younis H, Bartz S, Parry J, Ferrari N, Henry SP, Levin AA. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol 2012;30:920-3. [PMID: 23051805 DOI: 10.1038/nbt.2376] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
2 Olesen MTJ, Ballarín-gonzález B, Howard KA. The application of RNAi-based treatments for inflammatory bowel disease. Drug Deliv and Transl Res 2014;4:4-18. [DOI: 10.1007/s13346-013-0156-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
3 Robles-Oteiza C, Taylor S, Yates T, Cicchini M, Lauderback B, Cashman CR, Burds AA, Winslow MM, Jacks T, Feldser DM. Recombinase-based conditional and reversible gene regulation via XTR alleles. Nat Commun 2015;6:8783. [PMID: 26537451 DOI: 10.1038/ncomms9783] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cui J, Song Y, Han X, Hu J, Chen Y, Chen X, Xu X, Xing Y, Lu H, Cai L. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling. Front Oncol 2020;10:542007. [PMID: 33123465 DOI: 10.3389/fonc.2020.542007] [Reference Citation Analysis]
5 Watson LM, Wood MJ. RNA therapy for polyglutamine neurodegenerative diseases. Expert Rev Mol Med 2012;14:e3. [PMID: 22293529 DOI: 10.1017/erm.2011.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
6 Millings EJ, De Rosa MC, Fleet S, Watanabe K, Rausch R, Egli D, Li G, Leduc CA, Zhang Y, Fischer SG, Leibel RL. ILDR2 has a negligible role in hepatic steatosis. PLoS One 2018;13:e0197548. [PMID: 29847571 DOI: 10.1371/journal.pone.0197548] [Reference Citation Analysis]
7 Guo J, Bourre L, Soden DM, O'sullivan GC, O'driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnology Advances 2011;29:402-17. [DOI: 10.1016/j.biotechadv.2011.03.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 7.1] [Reference Citation Analysis]
8 Flamini S, Sergeev P, Viana de Barros Z, Mello T, Biagioli M, Paglialunga M, Fiorucci C, Prikazchikova T, Pagano S, Gagliardi A, Riccardi C, Zatsepin T, Migliorati G, Bereshchenko O, Bruscoli S. Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment. Cell Death Dis 2021;12:421. [PMID: 33927191 DOI: 10.1038/s41419-021-03704-w] [Reference Citation Analysis]
9 Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26:9377-86. [PMID: 17000754 DOI: 10.1128/MCB.01229-06] [Cited by in Crossref: 136] [Cited by in F6Publishing: 70] [Article Influence: 8.5] [Reference Citation Analysis]
10 Sigoillot FD, King RW. Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 2011;6:47-60. [PMID: 21142076 DOI: 10.1021/cb100358f] [Cited by in Crossref: 88] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
11 Shim MS, Wong S, Kwon YJ. siRNA as a conventional drug in the clinic? Challenges and current technologies. Drug Discovery Today: Technologies 2012;9:e167-73. [DOI: 10.1016/j.ddtec.2012.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
12 Zhou C, Chattopadhyaya J. Intramolecular free-radical cyclization reactions on pentose sugars for the synthesis of carba-LNA and carba-ENA and the application of their modified oligonucleotides as potential RNA targeted therapeutics. Chem Rev 2012;112:3808-32. [PMID: 22530946 DOI: 10.1021/cr100306q] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
13 Roberts TC, Ezzat K, El Andaloussi S, Weinberg MS. Synthetic SiRNA Delivery: Progress and Prospects. In: Shum K, Rossi J, editors. SiRNA Delivery Methods. New York: Springer; 2016. pp. 291-310. [DOI: 10.1007/978-1-4939-3112-5_23] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
14 Horn T, Boutros M. Design of RNAi reagents for invertebrate model organisms and human disease vectors. Methods Mol Biol 2013;942:315-46. [PMID: 23027059 DOI: 10.1007/978-1-62703-119-6_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Scheele C, Larsson O, Timmons JA. Using functional genomics to study PINK1 and metabolic physiology. Methods Enzymol 2009;457:211-29. [PMID: 19426870 DOI: 10.1016/S0076-6879(09)05012-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Li H, Mar BG, Zhang H, Puram RV, Vazquez F, Weir BA, Hahn WC, Ebert B, Pellman D. The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 2017;129:497-508. [PMID: 27756750 DOI: 10.1182/blood-2016-05-714493] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
17 Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61:746-759. [PMID: 19389436 DOI: 10.1016/j.addr.2009.04.004] [Cited by in Crossref: 324] [Cited by in F6Publishing: 304] [Article Influence: 24.9] [Reference Citation Analysis]
18 Fokina AA, Stetsenko DA, François JC. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes. Expert Opin Biol Ther 2015;15:689-711. [PMID: 25772532 DOI: 10.1517/14712598.2015.1025048] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 8.9] [Reference Citation Analysis]
19 Ui-Tei K, Nishi K, Takahashi T, Nagasawa T. Thermodynamic Control of Small RNA-Mediated Gene Silencing. Front Genet 2012;3:101. [PMID: 22675333 DOI: 10.3389/fgene.2012.00101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
20 Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, Higginbottom A, Myszczynska MA, Milo M, Hautbergue GM, Meyer K, Kaspar BK, Ferraiuolo L, Shaw PJ, Azzouz M. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Mol Ther Nucleic Acids 2018;12:75-88. [PMID: 30195799 DOI: 10.1016/j.omtn.2018.04.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
21 Chu HW, Rios C, Huang C, Wesolowska-Andersen A, Burchard EG, O'Connor BP, Fingerlin TE, Nichols D, Reynolds SD, Seibold MA. CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18. Gene Ther 2015;22:822-9. [PMID: 26043872 DOI: 10.1038/gt.2015.53] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
22 Hasan NM, Longacre MJ, Stoker SW, Kendrick MA, MacDonald MJ. Mitochondrial malic enzyme 3 is important for insulin secretion in pancreatic β-cells. Mol Endocrinol 2015;29:396-410. [PMID: 25594249 DOI: 10.1210/me.2014-1249] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
23 Colombo R, Moll J. Target validation to biomarker development: focus on RNA interference. Mol Diagn Ther 2008;12:63-70. [PMID: 18422370 DOI: 10.1007/BF03256271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Putzbach W, Gao QQ, Patel M, van Dongen S, Haluck-Kangas A, Sarshad AA, Bartom ET, Kim KA, Scholtens DM, Hafner M, Zhao JC, Murmann AE, Peter ME. Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism. Elife 2017;6:e29702. [PMID: 29063830 DOI: 10.7554/eLife.29702] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
25 Murali R, John PG, Peter S D. Soft computing model for optimized siRNA design by identifying off target possibilities using artificial neural network model. Gene 2015;562:152-8. [PMID: 25725126 DOI: 10.1016/j.gene.2015.02.067] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol 2011; 17(36): 4090-4098 [PMID: 22039322 DOI: 10.3748/wjg.v17.i36.4090] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
27 Zwang Y, Jonas O, Chen C, Rinne ML, Doench JG, Piccioni F, Tan L, Huang HT, Wang J, Ham YJ, O'Connell J, Bhola P, Doshi M, Whitman M, Cima M, Letai A, Root DE, Langer RS, Gray N, Hahn WC. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife 2017;6:e24523. [PMID: 28561737 DOI: 10.7554/eLife.24523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
28 Ueno Y, Yoshikawa K, Kitamura Y, Kitade Y. Effect of incorporation of alkyl linkers into siRNAs on RNA interference. Bioorg Med Chem Lett 2009;19:875-7. [PMID: 19095446 DOI: 10.1016/j.bmcl.2008.11.107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Mockenhaupt S, Grosse S, Rupp D, Bartenschlager R, Grimm D. Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys. Proc Natl Acad Sci U S A 2015;112:E4007-16. [PMID: 26170322 DOI: 10.1073/pnas.1510476112] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
30 Nguyen H, Wilson H, Jayakumar S, Kulkarni V, Kulkarni S. Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System. Viruses 2021;13:1850. [PMID: 34578431 DOI: 10.3390/v13091850] [Reference Citation Analysis]
31 Baum P, Fundel-Clemens K, Kreuz S, Kontermann RE, Weith A, Mennerich D, Rippmann JF. Off-target analysis of control siRNA molecules reveals important differences in the cytokine profile and inflammation response of human fibroblasts. Oligonucleotides 2010;20:17-26. [PMID: 20038253 DOI: 10.1089/oli.2009.0213] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
32 Yang JS, Lai EC. Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates. Cell Cycle 2010;9:4455-60. [PMID: 21088485 DOI: 10.4161/cc.9.22.13958] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
33 Wang P, Zhou Y, Richards AM. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry. Theranostics 2021;11:8771-96. [PMID: 34522211 DOI: 10.7150/thno.62642] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Maczuga P, Lubelski J, van Logtenstein R, Borel F, Blits B, Fakkert E, Costessi A, Butler D, van Deventer S, Petry H, Koornneef A, Konstantinova P. Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy. Mol Ther 2013;21:217-27. [PMID: 23089734 DOI: 10.1038/mt.2012.160] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
35 Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84-87. [PMID: 24336571 DOI: 10.1126/science.1247005] [Cited by in Crossref: 2856] [Cited by in F6Publishing: 2444] [Article Influence: 317.3] [Reference Citation Analysis]
36 Anderson E, Boese Q, Khvorova A, Karpilow J. Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol 2008;442:45-63. [PMID: 18369777 DOI: 10.1007/978-1-59745-191-8_4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
37 Ehsani A, Saetrom P, Zhang J, Alluin J, Li H, Snøve O Jr, Aagaard L, Rossi JJ. Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. Mol Ther 2010;18:796-802. [PMID: 20104214 DOI: 10.1038/mt.2009.321] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
38 Weninger A, Killinger M, Vogl T. Key Methods for Synthetic Biology: Genome Engineering and DNA Assembly. In: Glieder A, Kubicek CP, Mattanovich D, Wiltschi B, Sauer M, editors. Synthetic Biology. Cham: Springer International Publishing; 2016. pp. 101-41. [DOI: 10.1007/978-3-319-22708-5_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Huh JR, Foe I, Muro I, Chen CH, Seol JH, Yoo SJ, Guo M, Park JM, Hay BA. The Drosophila inhibitor of apoptosis (IAP) DIAP2 is dispensable for cell survival, required for the innate immune response to gram-negative bacterial infection, and can be negatively regulated by the reaper/hid/grim family of IAP-binding apoptosis inducers. J Biol Chem. 2007;282:2056-2068. [PMID: 17068333 DOI: 10.1074/jbc.M608051200] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
40 Shao Y, Chan CY, Maliyekkel A, Lawrence CE, Roninson IB, Ding Y. Effect of target secondary structure on RNAi efficiency. RNA 2007;13:1631-40. [PMID: 17684233 DOI: 10.1261/rna.546207] [Cited by in Crossref: 117] [Cited by in F6Publishing: 100] [Article Influence: 7.8] [Reference Citation Analysis]
41 Liu J, Guo B. RNA-based therapeutics for colorectal cancer: Updates and future directions. Pharmacol Res 2020;152:104550. [PMID: 31866285 DOI: 10.1016/j.phrs.2019.104550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
42 Piskun CM, Stein TJ. β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet Comp Oncol 2016;14:e4-e16. [PMID: 24256430 DOI: 10.1111/vco.12077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
43 Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 2012;1:e34. [PMID: 23552467 DOI: 10.1038/oncsis.2012.34] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
44 Klinghoffer RA, Roberts B, Annis J, Frazier J, Lewis P, Linsley PS, Cleary MA. An optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-5 inhibitor sensitivity. Assay Drug Dev Technol 2008;6:105-19. [PMID: 18205551 DOI: 10.1089/adt.2007.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
45 Sun G, Wang J, Huang Y, Yuan CW, Zhang K, Hu S, Chen L, Lin RJ, Yen Y, Riggs AD. Differences in silencing of mismatched targets by sliced versus diced siRNAs. Nucleic Acids Res 2018;46:6806-22. [PMID: 29718312 DOI: 10.1093/nar/gky287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
46 Petri S, Meister G. siRNA Design Principles and Off-Target Effects. In: Moll J, Colombo R, editors. Target Identification and Validation in Drug Discovery. Totowa: Humana Press; 2013. pp. 59-71. [DOI: 10.1007/978-1-62703-311-4_4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
47 Timms RT, Menzies SA, Tchasovnikarova IA, Christensen LC, Williamson JC, Antrobus R, Dougan G, Ellgaard L, Lehner PJ. Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens. Nat Commun 2016;7:11786. [PMID: 27283361 DOI: 10.1038/ncomms11786] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
48 Bennasser Y, Yeung ML, Jeang KT. RNAi therapy for HIV infection: principles and practicalities. BioDrugs 2007;21:17-22. [PMID: 17263586 DOI: 10.2165/00063030-200721010-00003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
49 Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 2006;12:1197-1205. [PMID: 16682562 DOI: 10.1261/rna.30706] [Cited by in Crossref: 536] [Cited by in F6Publishing: 513] [Article Influence: 33.5] [Reference Citation Analysis]
50 Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci 2020;63:485-500. [PMID: 31054052 DOI: 10.1007/s11427-018-9438-y] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
51 Zhang J, Zheng J, Lu C, Du Q, Liang Z, Xi Z. Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects. Chembiochem 2012;13:1940-5. [PMID: 22887813 DOI: 10.1002/cbic.201200349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
52 Gemayel MC, Bhatwadekar AD, Ciulla T. RNA therapeutics for retinal diseases. Expert Opin Biol Ther 2021;21:603-13. [PMID: 33307874 DOI: 10.1080/14712598.2021.1856365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Rong Y, Nakamura S, Hirata T, Motooka D, Liu YS, He ZA, Gao XD, Maeda Y, Kinoshita T, Fujita M. Genome-Wide Screening of Genes Required for Glycosylphosphatidylinositol Biosynthesis. PLoS One 2015;10:e0138553. [PMID: 26383639 DOI: 10.1371/journal.pone.0138553] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
54 Glazier DA, Liao J, Roberts BL, Li X, Yang K, Stevens CM, Tang W. Chemical Synthesis and Biological Application of Modified Oligonucleotides. Bioconjug Chem 2020;31:1213-33. [PMID: 32227878 DOI: 10.1021/acs.bioconjchem.0c00060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
55 Booker M, Samsonova AA, Kwon Y, Flockhart I, Mohr SE, Perrimon N. False negative rates in Drosophila cell-based RNAi screens: a case study. BMC Genomics 2011;12:50. [PMID: 21251254 DOI: 10.1186/1471-2164-12-50] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
56 Krausz E. High-content siRNA screening. Mol BioSyst 2007;3:232. [DOI: 10.1039/b616187c] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
57 Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 2010;38:789-802. [PMID: 20620952 DOI: 10.1016/j.molcel.2010.06.005] [Cited by in Crossref: 418] [Cited by in F6Publishing: 409] [Article Influence: 34.8] [Reference Citation Analysis]
58 Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M, Roehl I, Morskaya SS, Martinello R, Kahn J, Van Ranst M, Tripp RA, DeVincenzo JP, Pandey R, Maier M, Nechev L, Manoharan M, Kotelianski V, Meyers R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009;53:3952-62. [PMID: 19506055 DOI: 10.1128/AAC.00014-09] [Cited by in Crossref: 95] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
59 Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 2009;27:549-555. [PMID: 19465925 DOI: 10.1038/nbt.1543] [Cited by in Crossref: 229] [Cited by in F6Publishing: 288] [Article Influence: 17.6] [Reference Citation Analysis]
60 Chu Y, Kilikevicius A, Liu J, Johnson KC, Yokota S, Corey DR. Argonaute binding within 3'-untranslated regions poorly predicts gene repression. Nucleic Acids Res 2020;48:7439-53. [PMID: 32501500 DOI: 10.1093/nar/gkaa478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Buehler E, Khan AA, Marine S, Rajaram M, Bahl A, Burchard J, Ferrer M. siRNA off-target effects in genome-wide screens identify signaling pathway members. Sci Rep 2012;2:428. [PMID: 22645644 DOI: 10.1038/srep00428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
62 Keaney J, Campbell M, Humphries P. From RNA interference technology to effective therapy: how far have we come and how far to go? Ther Deliv 2011;2:1395-406. [PMID: 22826872 DOI: 10.4155/tde.11.109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 2016;351:1214-8. [PMID: 26912360 DOI: 10.1126/science.aad5214] [Cited by in Crossref: 212] [Cited by in F6Publishing: 188] [Article Influence: 35.3] [Reference Citation Analysis]
64 Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226:365-379. [PMID: 22069063 DOI: 10.1002/path.2993] [Cited by in Crossref: 243] [Cited by in F6Publishing: 222] [Article Influence: 22.1] [Reference Citation Analysis]
65 Li C, Kasinski AL. InVivo Cancer-Based Functional Genomics. Trends Cancer 2020;6:1002-17. [PMID: 32828714 DOI: 10.1016/j.trecan.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Avital A, Muzika NS, Persky Z, Karny A, Bar G, Michaeli Y, Shklover J, Shainsky J, Weissman H, Shoseyov O, Schroeder A. Foliar Delivery of siRNA Particles for Treating Viral Infections in Agricultural Grapevines. Adv Funct Mater 2021;31:2101003. [PMID: 34744552 DOI: 10.1002/adfm.202101003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Patil BL, Ogwok E, Wagaba H, Mohammed IU, Yadav JS, Bagewadi B, Taylor NJ, Kreuze JF, Maruthi MN, Alicai T, Fauquet CM. RNAi-mediated resistance to diverse isolates belonging to two virus species involved in Cassava brown streak disease. Mol Plant Pathol 2011;12:31-41. [PMID: 21118347 DOI: 10.1111/j.1364-3703.2010.00650.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
68 Srivatsa S, Kuipers J, Schmich F, Eicher S, Emmenlauer M, Dehio C, Beerenwinkel N. Improved pathway reconstruction from RNA interference screens by exploiting off-target effects. Bioinformatics 2018;34:i519-27. [PMID: 29950000 DOI: 10.1093/bioinformatics/bty240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
69 Shafi G, Aliya N, Munshi A. MicroRNA signatures in neurological disorders. Can J Neurol Sci 2010;37:177-85. [PMID: 20437927 DOI: 10.1017/s0317167100009902] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
70 Caffrey LM, deRonde BM, Minter LM, Tew GN. Mapping Optimal Charge Density and Length of ROMP-Based PTDMs for siRNA Internalization. Biomacromolecules 2016;17:3205-12. [PMID: 27599388 DOI: 10.1021/acs.biomac.6b00900] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
71 Kilikevicius A, Meister G, Corey DR. Reexamining assumptions about miRNA-guided gene silencing. Nucleic Acids Res 2021:gkab1256. [PMID: 34967419 DOI: 10.1093/nar/gkab1256] [Reference Citation Analysis]
72 Yao Z, Petschnigg J, Ketteler R, Stagljar I. Application guide for omics approaches to cell signaling. Nat Chem Biol 2015;11:387-97. [DOI: 10.1038/nchembio.1809] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
73 Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One 2011;6:e17031. [PMID: 21347396 DOI: 10.1371/journal.pone.0017031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
74 Swamy MN, Wu H, Shankar P. Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev 2016;103:174-86. [PMID: 27013255 DOI: 10.1016/j.addr.2016.03.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
75 Valenzuela RA, Onizuka K, Ball-Jones AA, Hu T, Suter SR, Beal PA. Guide Strand 3'-End Modifications Regulate siRNA Specificity. Chembiochem 2016;17:2340-5. [PMID: 27731539 DOI: 10.1002/cbic.201600453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
76 Hirsch AJ. The use of RNAi-based screens to identify host proteins involved in viral replication. Future Microbiol 2010;5:303-11. [PMID: 20143951 DOI: 10.2217/fmb.09.121] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
77 Bono JM, Olesnicky EC, Matzkin LM. Connecting genotypes, phenotypes and fitness: harnessing the power of CRISPR/Cas9 genome editing. Mol Ecol 2015;24:3810-22. [PMID: 26033315 DOI: 10.1111/mec.13252] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
78 Cullen BR. Enhancing and confirming the specificity of RNAi experiments. Nat Methods 2006;3:677-81. [DOI: 10.1038/nmeth913] [Cited by in Crossref: 123] [Cited by in F6Publishing: 124] [Article Influence: 7.7] [Reference Citation Analysis]
79 Singh Y, Tomar S, Khan S, Meher JG, Pawar VK, Raval K, Sharma K, Singh PK, Chaurasia M, Surendar Reddy B, Chourasia MK. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. J Control Release 2015;220:368-87. [PMID: 26528900 DOI: 10.1016/j.jconrel.2015.10.050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
80 Watanabe T, Umehara T, Kohara M. Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Deliv Rev 2007;59:1263-76. [PMID: 17822803 DOI: 10.1016/j.addr.2007.03.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
81 Hultquist JF, Hiatt J, Schumann K, McGregor MJ, Roth TL, Haas P, Doudna JA, Marson A, Krogan NJ. CRISPR-Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV-host factor interactions. Nat Protoc 2019;14:1-27. [PMID: 30559373 DOI: 10.1038/s41596-018-0069-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
82 Rasmussen SH, Jacobsen A, Krogh A. cWords - systematic microRNA regulatory motif discovery from mRNA expression data. Silence 2013;4:2. [PMID: 23688306 DOI: 10.1186/1758-907X-4-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
83 Singh SK, Gaur RK. Progress towards Therapeutic Application of RNA Interference for HIV Infection: . BioDrugs 2009;23:269-76. [DOI: 10.2165/11317120-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
84 Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 2008;16:947-56. [PMID: 18388917 DOI: 10.1038/mt.2008.50] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 7.7] [Reference Citation Analysis]
85 Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129:303-317. [PMID: 17397913 DOI: 10.1016/j.cell.2007.03.030] [Cited by in Crossref: 1007] [Cited by in F6Publishing: 926] [Article Influence: 67.1] [Reference Citation Analysis]
86 Petri S, Dueck A, Lehmann G, Putz N, Rüdel S, Kremmer E, Meister G. Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA. 2011;17:737-749. [PMID: 21367974 DOI: 10.1261/rna.2348111] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
87 Alemán LM, Doench J, Sharp PA. Comparison of siRNA-induced off-target RNA and protein effects. RNA 2007;13:385-95. [PMID: 17237357 DOI: 10.1261/rna.352507] [Cited by in Crossref: 100] [Cited by in F6Publishing: 102] [Article Influence: 6.7] [Reference Citation Analysis]
88 Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids 2015;4:e252. [PMID: 26372022 DOI: 10.1038/mtna.2015.23] [Cited by in Crossref: 368] [Cited by in F6Publishing: 350] [Article Influence: 52.6] [Reference Citation Analysis]
89 Kolanthai E, Fu Y, Kumar U, Babu B, Venkatesan AK, Liechty KW, Seal S. Nanoparticle mediated RNA delivery for wound healing. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1741. [PMID: 34369096 DOI: 10.1002/wnan.1741] [Reference Citation Analysis]
90 Chong R, Squires R, Swiss R, Agaisse H. RNAi screen reveals host cell kinases specifically involved in Listeria monocytogenes spread from cell to cell. PLoS One 2011;6:e23399. [PMID: 21853127 DOI: 10.1371/journal.pone.0023399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
91 Nierode G, Kwon PS, Dordick JS, Kwon SJ. Cell-Based Assay Design for High-Content Screening of Drug Candidates. J Microbiol Biotechnol 2016;26:213-25. [PMID: 26428732 DOI: 10.4014/jmb.1508.08007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
92 Nunes FM, Aleixo AC, Barchuk AR, Bomtorin AD, Grozinger CM, Simões ZL. Non-Target Effects of Green Fluorescent Protein (GFP)-Derived Double-Stranded RNA (dsRNA-GFP) Used in Honey Bee RNA Interference (RNAi) Assays. Insects 2013;4:90-103. [PMID: 26466797 DOI: 10.3390/insects4010090] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
93 Varley AJ, Hammill ML, Salim L, Desaulniers J. Effects of Chemical Modifications on siRNA Strand Selection in Mammalian Cells. Nucleic Acid Therapeutics 2020;30:229-36. [DOI: 10.1089/nat.2020.0848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zhong W, Shen WF, Ning BF, Hu PF, Lin Y, Yue HY, Yin C, Hou JL, Chen YX, Zhang JP. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology. 2009;50:1524-1536. [PMID: 19787807 DOI: 10.1002/hep.23189] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
95 Huang H, Qiao R, Zhao D, Zhang T, Li Y, Yi F, Lai F, Hong J, Ding X, Yang Z, Zhang L, Du Q, Liang Z. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res 2009;37:7560-9. [PMID: 19815667 DOI: 10.1093/nar/gkp835] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
96 Vickers TA, Sabripour M, Crooke ST. U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Res 2011;39:e71. [PMID: 21415007 DOI: 10.1093/nar/gkr150] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
97 Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet 2015;16:543-52. [PMID: 26281785 DOI: 10.1038/nrg3978] [Cited by in Crossref: 482] [Cited by in F6Publishing: 459] [Article Influence: 68.9] [Reference Citation Analysis]
98 Moffat J, Reiling JH, Sabatini DM. Off-target effects associated with long dsRNAs in Drosophila RNAi screens. Trends in Pharmacological Sciences 2007;28:149-51. [DOI: 10.1016/j.tips.2007.02.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
99 Kamola PJ, Nakano Y, Takahashi T, Wilson PA, Ui-Tei K. The siRNA Non-seed Region and Its Target Sequences Are Auxiliary Determinants of Off-Target Effects. PLoS Comput Biol 2015;11:e1004656. [PMID: 26657993 DOI: 10.1371/journal.pcbi.1004656] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
100 Guennewig B, Stoltz M, Menzi M, Dogar AM, Hall J. Properties of N(4)-methylated cytidines in miRNA mimics. Nucleic Acid Ther 2012;22:109-16. [PMID: 22373008 DOI: 10.1089/nat.2011.0329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
101 Suter SR, Sheu-Gruttadauria J, Schirle NT, Valenzuela R, Ball-Jones AA, Onizuka K, MacRae IJ, Beal PA. Structure-Guided Control of siRNA Off-Target Effects. J Am Chem Soc 2016;138:8667-9. [PMID: 27387838 DOI: 10.1021/jacs.6b06137] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
102 Kawata E, Ashihara E, Maekawa T. RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma 2011;1:6. [PMID: 21884621 DOI: 10.1186/2043-9113-1-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
103 Kittler R, Surendranath V, Heninger AK, Slabicki M, Theis M, Putz G, Franke K, Caldarelli A, Grabner H, Kozak K, Wagner J, Rees E, Korn B, Frenzel C, Sachse C, Sönnichsen B, Guo J, Schelter J, Burchard J, Linsley PS, Jackson AL, Habermann B, Buchholz F. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat Methods 2007;4:337-44. [PMID: 17351622 DOI: 10.1038/nmeth1025] [Cited by in Crossref: 139] [Cited by in F6Publishing: 125] [Article Influence: 9.3] [Reference Citation Analysis]
104 Saito T, Sætrom P. Target gene expression levels and competition between transfected and endogenous microRNAs are strong confounding factors in microRNA high-throughput experiments. Silence 2012;3:3. [PMID: 22325809 DOI: 10.1186/1758-907X-3-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
105 Darnell M, Karlsson JE, Owen A, Hidalgo IJ, Li J, Zhang W, Andersson TB. Investigation of the Involvement of P-Glycoprotein and Multidrug Resistance-Associated Protein 2 in the Efflux of Ximelagatran and Its Metabolites by Using Short Hairpin RNA Knockdown in Caco-2 Cells. Drug Metab Dispos 2010;38:491-7. [DOI: 10.1124/dmd.109.029967] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
106 Rodrigues TB, Petrick JS. Safety Considerations for Humans and Other Vertebrates Regarding Agricultural Uses of Externally Applied RNA Molecules. Front Plant Sci 2020;11:407. [PMID: 32391029 DOI: 10.3389/fpls.2020.00407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
107 Michaels YS, Barnkob MB, Barbosa H, Baeumler TA, Thompson MK, Andre V, Colin-York H, Fritzsche M, Gileadi U, Sheppard HM, Knapp DJHF, Milne TA, Cerundolo V, Fulga TA. Precise tuning of gene expression levels in mammalian cells. Nat Commun 2019;10:818. [PMID: 30778069 DOI: 10.1038/s41467-019-08777-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
108 Lai A, Cairns MJ, Tran N, Zhang HP, Cullen L, Arndt GM. RNA modulators of complex phenotypes in mammalian cells. PLoS One. 2009;4:e4758. [PMID: 19270743 DOI: 10.1371/journal.pone.0004758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
109 Kiss DL, Andrulis ED. Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits. RNA 2010;16:781-91. [PMID: 20185544 DOI: 10.1261/rna.1906710] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
110 Romano G, Acunzo M, Nana-Sinkam P. microRNAs as Novel Therapeutics in Cancer. Cancers (Basel) 2021;13:1526. [PMID: 33810332 DOI: 10.3390/cancers13071526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Tschaharganeh D, Ehemann V, Nussbaum T, Schirmacher P, Breuhahn K. Non-specific effects of siRNAs on tumor cells with implications on therapeutic applicability using RNA interference. Pathol Oncol Res 2007;13:84-90. [DOI: 10.1007/bf02893482] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
112 Ma J, Flemr M, Stein P, Berninger P, Malik R, Zavolan M, Svoboda P, Schultz RM. MicroRNA activity is suppressed in mouse oocytes. Curr Biol 2010;20:265-70. [PMID: 20116252 DOI: 10.1016/j.cub.2009.12.042] [Cited by in Crossref: 175] [Cited by in F6Publishing: 165] [Article Influence: 14.6] [Reference Citation Analysis]
113 Wade M. High-Throughput Silencing Using the CRISPR-Cas9 System: A Review of the Benefits and Challenges. J Biomol Screen 2015;20:1027-39. [PMID: 26001564 DOI: 10.1177/1087057115587916] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
114 Zamanian-daryoush M, Marques JT, Gantier MP, Behlke MA, John M, Rayman P, Finke J, Williams BR. Determinants of Cytokine Induction by Small Interfering RNA in Human Peripheral Blood Mononuclear Cells. Journal of Interferon & Cytokine Research 2008;28:221-33. [DOI: 10.1089/jir.2007.0090] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
115 Boudreau RL, Spengler RM, Hylock RH, Kusenda BJ, Davis HA, Eichmann DA, Davidson BL. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res 2013;41:e9. [PMID: 22941647 DOI: 10.1093/nar/gks797] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
116 Gatta AK, Hariharapura RC, Udupa N, Reddy MS, Josyula VR. Strategies for improving the specificity of siRNAs for enhanced therapeutic potential. Expert Opin Drug Discov 2018;13:709-25. [PMID: 29902093 DOI: 10.1080/17460441.2018.1480607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Ittig D, Luisier S, Weiler J, Schümperli D, Leumann CJ. Improving gene silencing of siRNAs via tricyclo-DNA modification. Artif DNA PNA XNA 2010;1:9-16. [PMID: 21687522 DOI: 10.4161/adna.1.1.11385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
118 Clanton-Arrowood K, McGurk J, Schroeder SJ. 3' terminal nucleotides determine thermodynamic stabilities of mismatches at the ends of RNA helices. Biochemistry 2008;47:13418-27. [PMID: 19053257 DOI: 10.1021/bi801594k] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
119 Vaish N, Chen F, Seth S, Fosnaugh K, Liu Y, Adami R, Brown T, Chen Y, Harvie P, Johns R, Severson G, Granger B, Charmley P, Houston M, Templin MV, Polisky B. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 2011;39:1823-32. [PMID: 21047800 DOI: 10.1093/nar/gkq961] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
120 Lee SH, Cunha D, Piermarocchi C, Paternostro G, Pinkerton A, Ladriere L, Marchetti P, Eizirik DL, Cnop M, Levine F. High-throughput screening and bioinformatic analysis to ascertain compounds that prevent saturated fatty acid-induced β-cell apoptosis. Biochem Pharmacol 2017;138:140-9. [PMID: 28522407 DOI: 10.1016/j.bcp.2017.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
121 Anesti AM, Coffin RS. Delivery of RNA interference triggers to sensory neurons in vivo using herpes simplex virus. Expert Opin Biol Ther 2010;10:89-103. [PMID: 20420517 DOI: 10.1517/14712590903379486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
122 Yuan NN, Cai CZ, Wu MY, Zhu Q, Su H, Li M, Ren J, Tan JQ, Lu JH. Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology. Front Pharmacol 2019;10:16. [PMID: 30745870 DOI: 10.3389/fphar.2019.00016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
123 Omahen DA. MicroRNA and Diseases of the Nervous System: . Neurosurgery 2011;69:440-54. [DOI: 10.1227/neu.0b013e318215a3b3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
124 Singh SK. RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther 2008;8:449-61. [PMID: 18352849 DOI: 10.1517/14712598.8.4.449] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
125 Senapati D, Patra BC, Kar A, Chini DS, Ghosh S, Patra S, Bhattacharya M. Promising approaches of small interfering RNAs (siRNAs) mediated cancer gene therapy. Gene 2019;719:144071. [PMID: 31454539 DOI: 10.1016/j.gene.2019.144071] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
126 Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 2020;19:673-94. [PMID: 32782413 DOI: 10.1038/s41573-020-0075-7] [Cited by in Crossref: 193] [Cited by in F6Publishing: 183] [Article Influence: 96.5] [Reference Citation Analysis]
127 Passioura T, Gozar MM, Goodchild A, King A, Arndt GM, Poidinger M, Birkett DJ, Rivory LP. Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnol 2009;9:57. [PMID: 19531249 DOI: 10.1186/1472-6750-9-57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
128 Dou HH, Mallari R, Pipathsouk A, Das A, Lo MC. An Automated High-Throughput Fluorescence In Situ Hybridization (FISH) Assay Platform for Use in the Identification and Optimization of siRNA-Based Therapeutics. SLAS Discov 2021;26:281-91. [PMID: 33016168 DOI: 10.1177/2472555220960045] [Reference Citation Analysis]
129 Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S, Panjwani A, Warnock LC, Douillard Guilloux GA, Moores K, Koppe EL, Wixted WE, Wilson PA, Gooderham NJ, Gant TW, Clark KL, Hughes SA, Edbrooke MR, Parry JD. In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res 2015;43:8638-50. [PMID: 26338776 DOI: 10.1093/nar/gkv857] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 8.9] [Reference Citation Analysis]
130 Cardoso AM, Calejo MT, Morais CM, Cardoso AL, Cruz R, Zhu K, Pedroso de Lima MC, Jurado AS, Nyström B. Application of Thermoresponsive PNIPAAM- b -PAMPTMA Diblock Copolymers in siRNA Delivery. Mol Pharmaceutics 2014;11:819-27. [DOI: 10.1021/mp400510a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
131 Zhang Y, Friedlander RM. Silencing Huntington’s Disease Gene with RNAi. In: Erdmann VA, Barciszewski J, editors. RNA Technologies and Their Applications. Berlin: Springer Berlin Heidelberg; 2010. pp. 131-60. [DOI: 10.1007/978-3-642-12168-5_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Pham KM, Suter SR, Lu SS, Beal PA. Ester modification at the 3' end of anti-microRNA oligonucleotides increases potency of microRNA inhibition. Bioorg Med Chem 2021;29:115894. [PMID: 33290908 DOI: 10.1016/j.bmc.2020.115894] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Coutinho MF, Santos JI, S Mendonça L, Matos L, Prata MJ, S Jurado A, Pedroso de Lima MC, Alves S. Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach. Int J Mol Sci 2020;21:E5732. [PMID: 32785133 DOI: 10.3390/ijms21165732] [Reference Citation Analysis]
134 Howard TP, Vazquez F, Tsherniak A, Hong AL, Rinne M, Aguirre AJ, Boehm JS, Hahn WC. Functional Genomic Characterization of Cancer Genomes. Cold Spring Harb Symp Quant Biol 2016;81:237-46. [PMID: 27815544 DOI: 10.1101/sqb.2016.81.031070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
135 Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 2009;16:807-9. [DOI: 10.1038/cgt.2009.53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
136 Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P, Mertens D. Off-target effects of siRNA specific for GFP. BMC Mol Biol. 2008;9:60. [PMID: 18577207 DOI: 10.1186/1471-2199-9-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Stehling O, Sheftel AD, Lill R. Chapter 12 Controlled expression of iron-sulfur cluster assembly components for respiratory chain complexes in mammalian cells. Methods Enzymol 2009;456:209-31. [PMID: 19348891 DOI: 10.1016/S0076-6879(08)04412-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
138 Dijkstra JM, Ballingall KT. Non-human lnc-DC orthologs encode Wdnm1-like protein. F1000Res 2014;3:160. [PMID: 25309733 DOI: 10.12688/f1000research.4711.2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
139 Lundstrom K. Viral Vectors Applied for RNAi-Based Antiviral Therapy. Viruses 2020;12:E924. [PMID: 32842491 DOI: 10.3390/v12090924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
140 Pasternak A, Wengel J. Unlocked nucleic acid--an RNA modification with broad potential. Org Biomol Chem 2011;9:3591-7. [PMID: 21431171 DOI: 10.1039/c0ob01085e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
141 Haussecker D. Stacking up CRISPR against RNAi for therapeutic gene inhibition. FEBS J 2016;283:3249-60. [PMID: 27090508 DOI: 10.1111/febs.13742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
142 Ahmed F, Senthil-Kumar M, Dai X, Ramu VS, Lee S, Mysore KS, Zhao PX. pssRNAit: A Web Server for Designing Effective and Specific Plant siRNAs with Genome-Wide Off-Target Assessment. Plant Physiol 2020;184:65-81. [PMID: 32651189 DOI: 10.1104/pp.20.00293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
143 Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Advanced Drug Delivery Reviews 2012;64:1508-21. [DOI: 10.1016/j.addr.2012.08.014] [Cited by in Crossref: 114] [Cited by in F6Publishing: 100] [Article Influence: 11.4] [Reference Citation Analysis]
144 Sillibourne JE, Hurbain I, Grand-Perret T, Goud B, Tran P, Bornens M. Primary ciliogenesis requires the distal appendage component Cep123. Biol Open 2013;2:535-45. [PMID: 23789104 DOI: 10.1242/bio.20134457] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
145 Alkan F, Wenzel A, Palasca O, Kerpedjiev P, Rudebeck AF, Stadler PF, Hofacker IL, Gorodkin J. RIsearch2: suffix array-based large-scale prediction of RNA-RNA interactions and siRNA off-targets. Nucleic Acids Res 2017;45:e60. [PMID: 28108657 DOI: 10.1093/nar/gkw1325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
146 Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 2009;6:569-75. [PMID: 19644458 DOI: 10.1038/nmeth.1351] [Cited by in Crossref: 419] [Cited by in F6Publishing: 378] [Article Influence: 32.2] [Reference Citation Analysis]
147 Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015;43:78-89. [PMID: 25385330 DOI: 10.1177/0192623314551840] [Cited by in Crossref: 135] [Cited by in F6Publishing: 121] [Article Influence: 16.9] [Reference Citation Analysis]
148 Qi WB, Hua RH, Yan LP, Tong GZ, Zhang GH, Ren T, Wu DL, Liao M. Effective inhibition of Japanese encephalitis virus replication by small interfering RNAs targeting the NS5 gene. Virus Res 2008;132:145-51. [PMID: 18190994 DOI: 10.1016/j.virusres.2007.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
149 Hannus M, Beitzinger M, Engelmann JC, Weickert MT, Spang R, Hannus S, Meister G. siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res 2014;42:8049-61. [PMID: 24875475 DOI: 10.1093/nar/gku480] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
150 Parker JS, Barford D. Argonaute: A scaffold for the function of short regulatory RNAs. Trends Biochem Sci 2006;31:622-30. [PMID: 17029813 DOI: 10.1016/j.tibs.2006.09.010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 6.6] [Reference Citation Analysis]
151 Matveeva OV, Nazipova NN, Ogurtsov AY, Shabalina SA. Optimized models for design of efficient miR30-based shRNAs. Front Genet 2012;3:163. [PMID: 22952469 DOI: 10.3389/fgene.2012.00163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
152 Cuajungco MP, Grimm C, Heller S. TRP channels as candidates for hearing and balance abnormalities in vertebrates. Biochim Biophys Acta 2007;1772:1022-7. [PMID: 17300924 DOI: 10.1016/j.bbadis.2007.01.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
153 Kittler R, Pelletier L, Heninger AK, Slabicki M, Theis M, Miroslaw L, Poser I, Lawo S, Grabner H, Kozak K, Wagner J, Surendranath V, Richter C, Bowen W, Jackson AL, Habermann B, Hyman AA, Buchholz F. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 2007;9:1401-12. [PMID: 17994010 DOI: 10.1038/ncb1659] [Cited by in Crossref: 226] [Cited by in F6Publishing: 225] [Article Influence: 15.1] [Reference Citation Analysis]
154 Momtazi AA, Banach M, Pirro M, Stein EA, Sahebkar A. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia? Clin Rev Allergy Immunol 2018;54:224-33. [PMID: 28534160 DOI: 10.1007/s12016-017-8611-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
155 Gemayel M, Byrne LC, Ciulla T, Sahel JA. Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies. Int Ophthalmol Clin 2021;61:35-57. [PMID: 34196317 DOI: 10.1097/IIO.0000000000000360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Yamato K, Yamada T, Kizaki M, Ui-Tei K, Natori Y, Fujino M, Nishihara T, Ikeda Y, Nasu Y, Saigo K, Yoshinouchi M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther 2008;15:140-53. [PMID: 18157144 DOI: 10.1038/sj.cgt.7701118] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
157 Ramachandran PS, Keiser MS, Davidson BL. Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics 2013;10:473-85. [PMID: 23589092 DOI: 10.1007/s13311-013-0183-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
158 Ahmed F, Dai X, Zhao PX. Bioinformatics tools for achieving better gene silencing in plants. Methods Mol Biol 2015;1287:43-60. [PMID: 25740355 DOI: 10.1007/978-1-4939-2453-0_3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
159 Nejepinska J, Flemr M, Svoboda P. Control of the interferon response in RNAi experiments. Methods Mol Biol 2012;820:133-61. [PMID: 22131030 DOI: 10.1007/978-1-61779-439-1_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Yoshikawa K, Ogata A, Matsuda C, Kohara M, Iba H, Kitade Y, Ueno Y. Incorporation of Biaryl Units into the 5′ and 3′ Ends of Sense and Antisense Strands of siRNA Duplexes Improves Strand Selectivity and Nuclease Resistance. Bioconjugate Chem 2011;22:42-9. [DOI: 10.1021/bc100301w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
161 Gumienny R, Zavolan M. Accurate transcriptome-wide prediction of microRNA targets and small interfering RNA off-targets with MIRZA-G. Nucleic Acids Res 2015;43:1380-91. [PMID: 25628353 DOI: 10.1093/nar/gkv050] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
162 Hutson TH, Foster E, Moon LD, Yáñez-Muñoz RJ. Lentiviral vector-mediated RNA silencing in the central nervous system. Hum Gene Ther Methods 2014;25:14-32. [PMID: 24090197 DOI: 10.1089/hgtb.2013.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
163 Herrera-Carrillo E, Harwig A, Berkhout B. Toward optimization of AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the top and bottom base pairs. RNA Biol 2015;12:447-56. [PMID: 25747107 DOI: 10.1080/15476286.2015.1022024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
164 Zhang X, Cheng C, Sun W, Wang H. Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy. In: Sioud M, editor. RNA Interference and CRISPR Technologies. New York: Springer US; 2020. pp. 419-33. [DOI: 10.1007/978-1-0716-0290-4_23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
165 Gimenez-Barcons M, Clotet B, Martinez MA. Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication. J Virol 2007;81:10680-6. [PMID: 17652404 DOI: 10.1128/JVI.00950-07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
166 Naito Y, Ui-Tei K. Designing functional siRNA with reduced off-target effects. Methods Mol Biol 2013;942:57-68. [PMID: 23027045 DOI: 10.1007/978-1-62703-119-6_3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
167 Hu R, Li H, Liu W, Yang L, Tan Y, Luo X. Targeting miRNAs in osteoblast differentiation and bone formation. Expert Opinion on Therapeutic Targets 2010;14:1109-20. [DOI: 10.1517/14728222.2010.512916] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
168 Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, Meister G. Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008;14:263-74. [PMID: 18094121 DOI: 10.1261/rna.789808] [Cited by in Crossref: 129] [Cited by in F6Publishing: 127] [Article Influence: 8.6] [Reference Citation Analysis]
169 Nikam RR, Gore KR. Journey of siRNA: Clinical Developments and Targeted Delivery. Nucleic Acid Ther 2018;28:209-24. [PMID: 29584585 DOI: 10.1089/nat.2017.0715] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
170 Shatizadeh Malekshahi S, Arefian E, Salimi V, Mokhtari Azad T, Yavarian J. Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design. Jundishapur J Microbiol 2016;9:e34304. [PMID: 27303618 DOI: 10.5812/jjm.34304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Nakayashiki H, Nguyen QB. RNA interference: roles in fungal biology. Curr Opin Microbiol 2008;11:494-502. [PMID: 18955156 DOI: 10.1016/j.mib.2008.10.001] [Cited by in Crossref: 86] [Cited by in F6Publishing: 66] [Article Influence: 6.1] [Reference Citation Analysis]
172 Zimmer AM, Pan YK, Chandrapalan T, Kwong RWM, Perry SF. Loss-of-function approaches in comparative physiology: is there a future for knockdown experiments in the era of genome editing? J Exp Biol 2019;222:jeb175737. [PMID: 30948498 DOI: 10.1242/jeb.175737] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
173 Wang F, Eagleson KL, Levitt P. Positive regulation of neocortical synapse formation by the Plexin-D1 receptor. Brain Res 2015;1616:157-65. [PMID: 25976775 DOI: 10.1016/j.brainres.2015.05.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
174 Fahim M, Larkin PJ. Designing effective amiRNA and multimeric amiRNA against plant viruses. Methods Mol Biol 2013;942:357-77. [PMID: 23027061 DOI: 10.1007/978-1-62703-119-6_19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
175 Haney SA. High-Content Screening Approaches That Minimize Confounding Factors in RNAi, CRISPR, and Small Molecule Screening. In: Johnston PA, Trask OJ, editors. High Content Screening. New York: Springer; 2018. pp. 113-30. [DOI: 10.1007/978-1-4939-7357-6_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
176 Dua P, Yoo JW, Kim S, Lee DK. Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther 2011;19:1676-87. [PMID: 21673662 DOI: 10.1038/mt.2011.109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
177 Henderson MJ, Singh OV, Zeitlin PL. Applications of proteomic technologies for understanding the premature proteolysis of CFTR. Expert Rev Proteomics 2010;7:473-86. [PMID: 20653504 DOI: 10.1586/epr.10.42] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
178 Battistella M, Marsden PA. Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference. Clin Pharmacol Ther 2015;97:79-87. [PMID: 25670385 DOI: 10.1002/cpt.8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
179 Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492-503. [PMID: 20544328 DOI: 10.1208/s12248-010-9210-4] [Cited by in Crossref: 471] [Cited by in F6Publishing: 445] [Article Influence: 39.3] [Reference Citation Analysis]
180 La Fauce K, Owens L. RNA interference with special reference to combating viruses of crustacea. Indian J Virol 2012;23:226-43. [PMID: 23997446 DOI: 10.1007/s13337-012-0084-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
181 Ballarín-González B, Thomsen TB, Howard KA. Clinical translation of RNAi-based treatments for respiratory diseases. Drug Deliv Transl Res 2013;3:84-99. [PMID: 25787868 DOI: 10.1007/s13346-012-0098-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
182 Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM, Meyers RM, Ali L, Goodale A, Lee Y, Jiang G, Hsiao J, Gerath WFJ, Howell S, Merkel E, Ghandi M, Garraway LA, Root DE, Golub TR, Boehm JS, Hahn WC. Defining a Cancer Dependency Map. Cell 2017;170:564-576.e16. [PMID: 28753430 DOI: 10.1016/j.cell.2017.06.010] [Cited by in Crossref: 754] [Cited by in F6Publishing: 601] [Article Influence: 150.8] [Reference Citation Analysis]
183 Berkhout B. Toward a durable anti-HIV gene therapy based on RNA interference. Ann N Y Acad Sci 2009;1175:3-14. [PMID: 19796072 DOI: 10.1111/j.1749-6632.2009.04972.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
184 Wei N, Zhang L, Huang H, Chen Y, Zheng J, Zhou X, Yi F, Du Q, Liang Z. siRNA has greatly elevated mismatch tolerance at 3'-UTR sites. PLoS One 2012;7:e49309. [PMID: 23145149 DOI: 10.1371/journal.pone.0049309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Chen B, Pan R, Askhatova D, Chen P. Effective small interfering RNA delivery in vitro via a new stearylated cationic peptide. Int J Nanomedicine 2015;10:3303-14. [PMID: 25999710 DOI: 10.2147/IJN.S79306] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
186 Yu AM, Choi YH, Tu MJ. RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev 2020;72:862-98. [PMID: 32929000 DOI: 10.1124/pr.120.019554] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
187 Koh HR, Ghanbariniaki A, Myong S. RNA stem structure governs coupling of dicing and gene silencing in RNA interference. Proc Natl Acad Sci U S A 2017;114:E10349-58. [PMID: 29133395 DOI: 10.1073/pnas.1710298114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
188 Crooke ST, Liang XH, Crooke RM, Baker BF, Geary RS. Antisense drug discovery and development technology considered in a pharmacological context. Biochem Pharmacol 2021;189:114196. [PMID: 32800852 DOI: 10.1016/j.bcp.2020.114196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
189 Tatiparti K, Sau S, Kashaw SK, Iyer AK. siRNA Delivery Strategies: A Comprehensive Review of Recent Developments. Nanomaterials (Basel) 2017;7:E77. [PMID: 28379201 DOI: 10.3390/nano7040077] [Cited by in Crossref: 181] [Cited by in F6Publishing: 161] [Article Influence: 36.2] [Reference Citation Analysis]
190 Tian S, Terai G, Kobayashi Y, Kimura Y, Abe H, Asai K, Ui-Tei K. A robust model for quantitative prediction of the silencing efficacy of wild-type and A-to-I edited miRNAs. RNA Biol 2020;17:264-80. [PMID: 31601146 DOI: 10.1080/15476286.2019.1678364] [Reference Citation Analysis]
191 Janitz M. Assigning functions to genes--the main challenge of the post-genomics era. Rev Physiol Biochem Pharmacol 2007;159:115-29. [PMID: 17846923 DOI: 10.1007/112_2007_0703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
192 Arvey A, Larsson E, Sander C, Leslie CS, Marks DS. Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol. 2010;6:363. [PMID: 20404830 DOI: 10.1038/msb.2010.24] [Cited by in Crossref: 226] [Cited by in F6Publishing: 232] [Article Influence: 18.8] [Reference Citation Analysis]
193 Jenkins BH, Maguire F, Leonard G, Eaton JD, West S, Housden BE, Milner DS, Richards TA. Emergent RNA-RNA interactions can promote stability in a facultative phototrophic endosymbiosis. Proc Natl Acad Sci U S A 2021;118:e2108874118. [PMID: 34521754 DOI: 10.1073/pnas.2108874118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Serva A, Claas C, Starkuviene V. A Potential of microRNAs for High-Content Screening. J Nucleic Acids 2011;2011:870903. [PMID: 21922044 DOI: 10.4061/2011/870903] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
195 Garber K. Alnylam terminates revusiran program, stock plunges. Nat Biotechnol 2016;34:1213-4. [DOI: 10.1038/nbt1216-1213] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
196 Taylor J, Woodcock S. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? J Biomol Screen 2015;20:1040-51. [PMID: 26048892 DOI: 10.1177/1087057115590069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
197 Li F, Mahato RI. RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev 2011;63:47-68. [PMID: 21156190 DOI: 10.1016/j.addr.2010.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
198 Daga N, Eicher S, Kannan A, Casanova A, Low SH, Kreibich S, Andritschke D, Emmenlauer M, Jenkins JL, Hardt WD, Greber UF, Dehio C, von Mering C. Growth-restricting effects of siRNA transfections: a largely deterministic combination of off-target binding and hybridization-independent competition. Nucleic Acids Res 2018;46:9309-20. [PMID: 30215772 DOI: 10.1093/nar/gky798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
199 Chen CJ, Cox JE, Kincaid RP, Martinez A, Sullivan CS. Divergent MicroRNA targetomes of closely related circulating strains of a polyomavirus. J Virol 2013;87:11135-47. [PMID: 23926342 DOI: 10.1128/JVI.01711-13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
200 Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplen NJ, Ried T. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2011;128:1069-79. [PMID: 20473941 DOI: 10.1002/ijc.25453] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Von Eije KJ, Berkhout B. RNA-interference-based Gene Therapy Approaches to HIV Type-1 Treatment: Tackling the Hurdles from Bench to Bedside. Antivir Chem Chemother 2009;19:221-33. [DOI: 10.1177/095632020901900602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
202 Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 2007;7:1021-34. [PMID: 17665991 DOI: 10.1517/14712598.7.7.1021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
203 Saito T, Sætrom P. A two-step site and mRNA-level model for predicting microRNA targets. BMC Bioinformatics 2010;11:612. [PMID: 21194446 DOI: 10.1186/1471-2105-11-612] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
204 Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods 2006;3:670-6. [DOI: 10.1038/nmeth911] [Cited by in Crossref: 210] [Cited by in F6Publishing: 189] [Article Influence: 13.1] [Reference Citation Analysis]
205 Seok H, Lee H, Jang ES, Chi SW. Evaluation and control of miRNA-like off-target repression for RNA interference. Cell Mol Life Sci 2018;75:797-814. [PMID: 28905147 DOI: 10.1007/s00018-017-2656-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
206 Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007;35:5886-97. [PMID: 17726057 DOI: 10.1093/nar/gkm548] [Cited by in Crossref: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.1] [Reference Citation Analysis]
207 Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2:711-9. [PMID: 17108989 DOI: 10.1038/nchembio839] [Cited by in Crossref: 744] [Cited by in F6Publishing: 703] [Article Influence: 46.5] [Reference Citation Analysis]
208 Nagata Y, Shimizu E, Hibio N, Ui-Tei K. Fluctuation of global gene expression by endogenous miRNA response to the introduction of an exogenous miRNA. Int J Mol Sci 2013;14:11171-89. [PMID: 23712357 DOI: 10.3390/ijms140611171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
209 Anderson EM, Birmingham A, Baskerville S, Reynolds A, Maksimova E, Leake D, Fedorov Y, Karpilow J, Khvorova A. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008;14:853-61. [PMID: 18367722 DOI: 10.1261/rna.704708] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 6.8] [Reference Citation Analysis]
210 Dahlgren C, Zhang HY, Du Q, Grahn M, Norstedt G, Wahlestedt C, Liang Z. Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res 2008;36:e53. [PMID: 18420656 DOI: 10.1093/nar/gkn190] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
211 Daniel-Carlier N, Sawafta A, Passet B, Thépot D, Leroux-Coyau M, Lefèvre F, Houdebine LM, Jolivet G. Viral infection resistance conferred on mice by siRNA transgenesis. Transgenic Res 2013;22:489-500. [PMID: 22961198 DOI: 10.1007/s11248-012-9649-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
212 Mook O, Vreijling J, Wengel SL, Wengel J, Zhou C, Chattopadhyaya J, Baas F, Fluiter K. In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. Artif DNA PNA XNA 2010;1:36-44. [PMID: 21687525 DOI: 10.4161/adna.1.1.12204] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
213 Danielsen MB, Wengel J. Cationic oligonucleotide derivatives and conjugates: A favorable approach for enhanced DNA and RNA targeting oligonucleotides. Beilstein J Org Chem 2021;17:1828-48. [PMID: 34386102 DOI: 10.3762/bjoc.17.125] [Reference Citation Analysis]
214 Deng H, Xu X, Hu L, Li J, Zhou D, Liu S, Luo P, He J, Weng S. A janus kinase from Scylla paramamosain activates JAK/STAT signaling pathway to restrain mud crab reovirus. Fish & Shellfish Immunology 2019;90:275-87. [DOI: 10.1016/j.fsi.2019.03.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
215 Tsui M, Xie T, Orth JD, Carpenter AE, Rudnicki S, Kim S, Shamu CE, Mitchison TJ. An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor. PLoS One 2009;4:e7339. [PMID: 19802393 DOI: 10.1371/journal.pone.0007339] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
216 Haley B, Hendrix D, Trang V, Levine M. A simplified miRNA-based gene silencing method for Drosophila melanogaster. Dev Biol 2008;321:482-90. [PMID: 18598689 DOI: 10.1016/j.ydbio.2008.06.015] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.4] [Reference Citation Analysis]
217 Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia 2017;31:934-44. [PMID: 27740635 DOI: 10.1038/leu.2016.280] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
218 Jiang M, Instrell R, Saunders B, Berven H, Howell M. Tales from an academic RNAi screening facility; FAQs. Brief Funct Genomics 2011;10:227-37. [PMID: 21527443 DOI: 10.1093/bfgp/elr016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
219 Kemppainen MJ, Pardo AG. pHg/pSILBAγ vector system for efficient gene silencing in homobasidiomycetes: optimization of ihpRNA - triggering in the mycorrhizal fungus Laccaria bicolor. Microb Biotechnol 2010;3:178-200. [PMID: 21255319 DOI: 10.1111/j.1751-7915.2009.00122.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
220 Sriram S, Robinson P, Pi L, Lewin AS, Schultz G. Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts. Invest Ophthalmol Vis Sci 2013;54:8214-23. [PMID: 24282226 DOI: 10.1167/iovs.13-12758] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
221 Doré-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, Rose SD, Beaudet N, Behlke MA, Sarret P. Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol Ther 2008;16:1331-9. [PMID: 18523447 DOI: 10.1038/mt.2008.98] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
222 Gonzalez-Alegre P, Paulson HL. Technology insight: therapeutic RNA interference--how far from the neurology clinic? Nat Clin Pract Neurol 2007;3:394-404. [PMID: 17611488 DOI: 10.1038/ncpneuro0551] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
223 Kuzma-Kozakiewicz M, Kwiecinski H. New therapeutic targets for amyotrophic lateral sclerosis. Expert Opin Ther Targets 2011;15:127-43. [PMID: 21133819 DOI: 10.1517/14728222.2011.542152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
224 Hagen J, Scheerlinck JP, Gasser RB. Knocking down schistosomes - promise for lentiviral transduction in parasites. Trends Parasitol 2015;31:324-32. [PMID: 25933926 DOI: 10.1016/j.pt.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
225 Li C, Liu Z, Yang F, Liu W, Wang D, Dong E, Wang Y, Wu CI, Lu X. siRNAs with decreased off-target effect facilitate the identification of essential genes in cancer cells. Oncotarget 2015;6:21603-13. [PMID: 26057633 DOI: 10.18632/oncotarget.4269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
226 Frizzi A, Zhang Y, Kao J, Hagen C, Huang S. Small RNA Profiles from Virus-Infected Fresh Market Vegetables. J Agric Food Chem 2014;62:12067-74. [DOI: 10.1021/jf503756v] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
227 Burchard J, Jackson AL, Malkov V, Needham RH, Tan Y, Bartz SR, Dai H, Sachs AB, Linsley PS. MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 2009;15:308-15. [PMID: 19144911 DOI: 10.1261/rna.1326809] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
228 Laganà A, Acunzo M, Romano G, Pulvirenti A, Veneziano D, Cascione L, Giugno R, Gasparini P, Shasha D, Ferro A, Croce CM. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 2014;42:5416-25. [PMID: 24627222 DOI: 10.1093/nar/gku202] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
229 Banerjee A, Banerjee C, Negi S, Chang J, Shukla P. Improvements in algal lipid production: a systems biology and gene editing approach. Critical Reviews in Biotechnology 2018;38:369-85. [DOI: 10.1080/07388551.2017.1356803] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 8.4] [Reference Citation Analysis]
230 Seinen E, Burgerhof JG, Jansen RC, Sibon OC. RNAi-induced off-target effects in Drosophila melanogaster: frequencies and solutions. Brief Funct Genomics 2011;10:206-14. [PMID: 21596801 DOI: 10.1093/bfgp/elr017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
231 Kamatuka K, Hattori M, Sugiyama T. shRNA target prediction informed by comprehensive enquiry (SPICE): a supporting system for high-throughput screening of shRNA library. EURASIP J Bioinform Syst Biol 2016;2016:7. [PMID: 26941783 DOI: 10.1186/s13637-016-0039-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
232 Ravon M, Berrera M, Ebeling M, Certa U. Single base mismatches in the mRNA target site allow specific seed region-mediated off-target binding of siRNA targeting human coagulation factor 7. RNA Biol 2012;9:87-97. [PMID: 22258146 DOI: 10.4161/rna.9.1.18121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
233 Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P, Mertens D. Off-target effects of siRNA specific for GFP. BMC Mol Biol 2008;9:60. [PMID: 18577207 DOI: 10.1186/1471-2199-9-60] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
234 Ahmed F, Senthil-Kumar M, Lee S, Dai X, Mysore KS, Zhao PX. Comprehensive analysis of small RNA-seq data reveals that combination of miRNA with its isomiRs increase the accuracy of target prediction in Arabidopsis thaliana. RNA Biol 2014;11:1414-29. [PMID: 25629686 DOI: 10.1080/15476286.2014.996474] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
235 Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, Zlatev I, Castoreno A, Xu H, Shulga-Morskaya S, Rajeev KG, Manoharan M, Keirstead ND, Maier MA, Jadhav V. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun 2018;9:723. [PMID: 29459660 DOI: 10.1038/s41467-018-02989-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 18.8] [Reference Citation Analysis]
236 Jacobsen A, Wen J, Marks DS, Krogh A. Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res. 2010;20:1010-1019. [PMID: 20508147 DOI: 10.1101/gr.103259.109] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.9] [Reference Citation Analysis]
237 ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006;14:883-892. [PMID: 16959541 DOI: 10.1016/j.ymthe.2006.07.007] [Cited by in Crossref: 226] [Cited by in F6Publishing: 224] [Article Influence: 14.1] [Reference Citation Analysis]
238 Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods. 2016;13:127-137. [PMID: 26820547 DOI: 10.1038/nmeth.3733] [Cited by in Crossref: 244] [Cited by in F6Publishing: 206] [Article Influence: 40.7] [Reference Citation Analysis]
239 Larsson E, Sander C, Marks D. mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol 2010;6:433. [PMID: 21081925 DOI: 10.1038/msb.2010.89] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 6.2] [Reference Citation Analysis]
240 Bellefroid C, Lechanteur A, Evrard B, Piel G. Lipid gene nanocarriers for the treatment of skin diseases: Current state-of-the-art. European Journal of Pharmaceutics and Biopharmaceutics 2019;137:95-111. [DOI: 10.1016/j.ejpb.2019.02.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
241 Bases R. Heat shock protein 70 (Hsp70)-stimulated deoxycytidine deaminases from a human lymphoma cell but not the activation-induced cytidine deaminase (AID) from Ramos 6.4 human Burkitt's lymphoma cells. Cell Stress Chaperones 2011;16:91-6. [PMID: 20680536 DOI: 10.1007/s12192-010-0213-y] [Reference Citation Analysis]
242 Kolenda T, Przybyła W, Teresiak A, Mackiewicz A, Lamperska KM. The mystery of let-7d - a small RNA with great power. Contemp Oncol (Pozn) 2014;18:293-301. [PMID: 25477749 DOI: 10.5114/wo.2014.44467] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
243 Karnati HK, Yalagala RS, Undi R, Pasupuleti SR, Gutti RK. Therapeutic potential of siRNA and DNAzymes in cancer. Tumour Biol 2014;35:9505-21. [PMID: 25149153 DOI: 10.1007/s13277-014-2477-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
244 Kabadi A, McDonnell E, Frank CL, Drowley L. Applications of Functional Genomics for Drug Discovery. SLAS Discov 2020;25:823-42. [PMID: 32026742 DOI: 10.1177/2472555220902092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Naito Y, Yoshimura J, Morishita S, Ui-Tei K. siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 2009;10:392. [PMID: 19948054 DOI: 10.1186/1471-2105-10-392] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 8.4] [Reference Citation Analysis]
246 Qiu L, Tan EK, Zeng L. microRNAs and Neurodegenerative Diseases. Adv Exp Med Biol 2015;888:85-105. [PMID: 26663180 DOI: 10.1007/978-3-319-22671-2_6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
247 Naito Y, Ui-Tei K. siRNA Design Software for a Target Gene-Specific RNA Interference. Front Genet 2012;3:102. [PMID: 22701467 DOI: 10.3389/fgene.2012.00102] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
248 Zhang P, Feng S, Liu G, Wang H, Fu A, Zhu H, Ren Q, Wang B, Xu X, Bai H, Dong C. CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradation. Oncogene 2016;35:5056-69. [PMID: 27041584 DOI: 10.1038/onc.2016.67] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
249 Eekels JJ, Berkhout B. Toward a durable treatment of HIV-1 infection using RNA interference. Prog Mol Biol Transl Sci 2011;102:141-63. [PMID: 21846571 DOI: 10.1016/B978-0-12-415795-8.00001-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
250 Liang XH, Hart CE, Crooke ST. Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochim Biophys Acta 2013;1829:455-68. [PMID: 23403288 DOI: 10.1016/j.bbagrm.2013.01.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
251 Elmes K, Schmich F, Szczurek E, Jenkins J, Beerenwinkel N, Gavryushkin A. Learning epistatic gene interactions from perturbation screens. PLoS One 2021;16:e0254491. [PMID: 34255784 DOI: 10.1371/journal.pone.0254491] [Reference Citation Analysis]
252 Fennell M, Commisso C, Ramirez C, Garippa R, Bar-Sagi D. High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis. Assay Drug Dev Technol 2015;13:347-55. [PMID: 26267765 DOI: 10.1089/adt.2015.660] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
253 Weinberg MS, Wood MJ. Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet 2009;18:R27-39. [PMID: 19297399 DOI: 10.1093/hmg/ddp070] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.4] [Reference Citation Analysis]
254 Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007;8:23-36. [PMID: 17183358 DOI: 10.1038/nrm2085] [Cited by in Crossref: 687] [Cited by in F6Publishing: 665] [Article Influence: 45.8] [Reference Citation Analysis]
255 Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C, Cleary MA. Reduced seed region-based off-target activity with lentivirus-mediated RNAi. RNA 2010;16:879-84. [PMID: 20348445 DOI: 10.1261/rna.1977810] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
256 Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol Aspects Med 2007;28:143-66. [PMID: 17307250 DOI: 10.1016/j.mam.2006.12.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
257 Ferrante P, Ballottari M, Bonente G, Giuliano G, Bassi R. LHCBM1 and LHCBM2/7 polypeptides, components of major LHCII complex, have distinct functional roles in photosynthetic antenna system of Chlamydomonas reinhardtii. J Biol Chem 2012;287:16276-88. [PMID: 22431727 DOI: 10.1074/jbc.M111.316729] [Cited by in Crossref: 65] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
258 Kitson JDA, Kamola PJ, Kane L. Hybridization-Dependent Effects. In: Ferrari N, Seguin R, editors. Oligonucleotide-Based Drugs and Therapeutics. Hoboken: John Wiley & Sons, Inc.; 2018. pp. 191-225. [DOI: 10.1002/9781119070153.ch7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
259 Jones CE, Tan WS, Grey F, Hughes DJ. Discovering antiviral restriction factors and pathways using genetic screens. J Gen Virol 2021;102. [PMID: 34020727 DOI: 10.1099/jgv.0.001603] [Reference Citation Analysis]
260 Zhang J, Chen Y, Huang Y, Jin HW, Qiao RP, Xing L, Zhang LR, Yang ZJ, Zhang LH. Synthesis and properties of novel L-isonucleoside modified oligonucleotides and siRNAs. Org Biomol Chem 2012;10:7566-77. [PMID: 22895883 DOI: 10.1039/c2ob26219c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
261 Markovsky E, Baabur-cohen H, Eldar-boock A, Omer L, Tiram G, Ferber S, Ofek P, Polyak D, Scomparin A, Satchi-fainaro R. Administration, distribution, metabolism and elimination of polymer therapeutics. Journal of Controlled Release 2012;161:446-60. [DOI: 10.1016/j.jconrel.2011.12.021] [Cited by in Crossref: 203] [Cited by in F6Publishing: 180] [Article Influence: 20.3] [Reference Citation Analysis]
262 Finnerty JR, Wang WX, Hébert SS, Wilfred BR, Mao G, Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402:491-509. [PMID: 20678503 DOI: 10.1016/j.jmb.2010.07.051] [Cited by in Crossref: 248] [Cited by in F6Publishing: 256] [Article Influence: 20.7] [Reference Citation Analysis]
263 Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res 2008;25:72-86. [PMID: 18074201 DOI: 10.1007/s11095-007-9504-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 5.3] [Reference Citation Analysis]
264 Vaish N, Agarwal P. The design, selection, and evaluation of highly specific and functional siRNA incorporating unlocked nucleobase analogs. Methods Mol Biol 2013;942:111-34. [PMID: 23027048 DOI: 10.1007/978-1-62703-119-6_6] [Reference Citation Analysis]
265 Yang C, Wang H, Qiao T, Yang B, Aliaga L, Qiu L, Tan W, Salameh J, McKenna-Yasek DM, Smith T, Peng L, Moore MJ, Brown RH Jr, Cai H, Xu Z. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2014;111:E1121-9. [PMID: 24616503 DOI: 10.1073/pnas.1322641111] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 11.1] [Reference Citation Analysis]
266 Laursen MB, Pakula MM, Gao S, Fluiter K, Mook OR, Baas F, Langklaer N, Wengel SL, Wengel J, Kjems J, Bramsen JB. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 2010;6:862-70. [PMID: 20567772 DOI: 10.1039/b918869j] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
267 De Souza EB, Cload ST, Pendergrast PS, Sah DW. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology 2009;34:142-58. [PMID: 18754007 DOI: 10.1038/npp.2008.115] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
268 Ukarapong S, Bao Y, Perera EM, Berkovitz GD. Megakaryocyte development is normal in mice with targeted disruption of Tescalcin. Exp Cell Res 2012;318:662-9. [PMID: 22285131 DOI: 10.1016/j.yexcr.2012.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
269 Snøve O Jr, Rossi JJ. Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol 2006;7:231. [PMID: 16942630 DOI: 10.1186/gb-2006-7-8-231] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
270 Bosgra S, Sipkens J, de Kimpe S, den Besten C, Datson N, van Deutekom J. The Pharmacokinetics of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy. Nucleic Acid Ther 2019;29:305-22. [PMID: 31429628 DOI: 10.1089/nat.2019.0805] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
271 Muhonen P, Holthofer H. Bioinformatic approaches to siRNA selection and optimization. Methods Mol Biol 2010;623:93-107. [PMID: 20217546 DOI: 10.1007/978-1-60761-588-0_6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
272 Elhefnawi M, Hassan N, Kamar M, Siam R, Remoli AL, El-azab I, Alaidy O, Marsili G, Sgarbanti M. The design of optimal therapeutic small interfering RNA molecules targeting diverse strains of influenza A virus. Bioinformatics 2011;27:3364-70. [DOI: 10.1093/bioinformatics/btr555] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
273 Ekman FK, Ojala DS, Adil MM, Lopez PA, Schaffer DV, Gaj T. CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model. Mol Ther Nucleic Acids 2019;17:829-39. [PMID: 31465962 DOI: 10.1016/j.omtn.2019.07.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
274 Su R, Fan LH, Cao C, Wang L, Du Z, Cai Z, Ouyang YC, Wang Y, Zhou Q, Wu L, Zhang N, Zhu X, Lei WL, Zhao H, Tian Y, He S, Wong CCL, Sun QY, Xue Y. Global profiling of RNA-binding protein target sites by LACE-seq. Nat Cell Biol 2021;23:664-75. [PMID: 34108658 DOI: 10.1038/s41556-021-00696-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
275 Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 2010;5:328-49. [PMID: 20043313 DOI: 10.1002/cmdc.200900444] [Cited by in Crossref: 142] [Cited by in F6Publishing: 129] [Article Influence: 11.8] [Reference Citation Analysis]
276 Nishi K, Takahashi T, Suzawa M, Miyakawa T, Nagasawa T, Ming Y, Tanokura M, Ui-Tei K. Control of the localization and function of a miRNA silencing component TNRC6A by Argonaute protein. Nucleic Acids Res 2015;43:9856-73. [PMID: 26446993 DOI: 10.1093/nar/gkv1026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
277 Liang M, Kamata M, Chen KN, Pariente N, An DS, Chen IS. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med 2010;12:255-65. [PMID: 20186995 DOI: 10.1002/jgm.1440] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
278 Barmania F, Pepper MS. C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Appl Transl Genom 2013;2:3-16. [PMID: 27942440 DOI: 10.1016/j.atg.2013.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
279 Teferi WM, Dodd K, Maranchuk R, Favis N, Evans DH. A whole-genome RNA interference screen for human cell factors affecting myxoma virus replication. J Virol 2013;87:4623-41. [PMID: 23408614 DOI: 10.1128/JVI.02617-12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
280 Sklan EH, Glenn JS. The Power of Silence: Application of Small Interfering RNAs to Gastrointestinal Diseases. Gastroenterology 2007;132:2291-5. [DOI: 10.1053/j.gastro.2007.04.056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
281 Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007;117:3633-41. [PMID: 18060021 DOI: 10.1172/JCI34129] [Cited by in Crossref: 111] [Cited by in F6Publishing: 41] [Article Influence: 7.9] [Reference Citation Analysis]
282 Ramasamy T, Munusamy S, Ruttala HB, Kim JO. Smart Nanocarriers for the Delivery of Nucleic Acid-Based Therapeutics: A Comprehensive Review. Biotechnol J 2021;16:e1900408. [PMID: 32702191 DOI: 10.1002/biot.201900408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
283 Teng X, Liu JY, Li D, Fang Y, Wang XY, Ma YX, Chen SJ, Zhao YX, Xu WZ, Gu HX. Application of allele-specific RNAi in hepatitis B virus lamivudine resistance. J Viral Hepat 2011;18:e491-8. [PMID: 21914068 DOI: 10.1111/j.1365-2893.2011.01483.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
284 Rasnic R, Linial N, Linial M. Enhancing identification of cancer types via lowly-expressed microRNAs. Nucleic Acids Res 2017;45:5048-60. [PMID: 28379430 DOI: 10.1093/nar/gkx210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
285 Huang W, Chen L, Kang L, Jin M, Sun P, Xin X, Gao Z, Bae YH. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs. Advanced Drug Delivery Reviews 2017;115:82-97. [DOI: 10.1016/j.addr.2017.06.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
286 Marimani MD, Ely A, Buff MC, Bernhardt S, Engels JW, Arbuthnot P. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem 2013;21:6145-55. [PMID: 23743442 DOI: 10.1016/j.bmc.2013.04.073] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
287 Fluiter K, Mook OR, Baas F. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol Biol 2009;487:189-203. [PMID: 19301648 DOI: 10.1007/978-1-60327-547-7_9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 21] [Article Influence: 0.5] [Reference Citation Analysis]
288 Angart P, Vocelle D, Chan C, Walton SP. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals (Basel) 2013;6:440-68. [PMID: 23976875 DOI: 10.3390/ph6040440] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
289 Zhou JF, Hua XG, Cui L, Zhu JG, Miao DN, Zou Y, He XZ, Su WG. Effective inhibition of porcine transmissible gastroenteritis virus replication in ST cells by shRNAs targeting RNA-dependent RNA polymerase gene. Antiviral Res 2007;74:36-42. [PMID: 17287033 DOI: 10.1016/j.antiviral.2006.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
290 Mazur S, Kozak K. Z' factor including siRNA design quality parameter in RNAi screening experiments. RNA Biol 2012;9:624-32. [PMID: 22614837 DOI: 10.4161/rna.19759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
291 Ballarín-gonzález B, Howard KA. Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions. Advanced Drug Delivery Reviews 2012;64:1717-29. [DOI: 10.1016/j.addr.2012.07.004] [Cited by in Crossref: 108] [Cited by in F6Publishing: 105] [Article Influence: 10.8] [Reference Citation Analysis]
292 Lundstrom K. Are Viral Vectors Any Good for RNAi Antiviral Therapy? Viruses 2020;12:E1189. [PMID: 33092124 DOI: 10.3390/v12101189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
293 Gil-Ranedo J, Mendiburu-Eliçabe M, García-Villanueva M, Medina D, del Álamo M, Izquierdo M. An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells. PLoS One 2011;6:e28753. [PMID: 22174890 DOI: 10.1371/journal.pone.0028753] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
294 Sijen T, Steiner FA, Thijssen KL, Plasterk RH. Secondary siRNAs result from unprimed RNA synthesis and form a distinct class. Science 2007;315:244-7. [PMID: 17158288 DOI: 10.1126/science.1136699] [Cited by in Crossref: 294] [Cited by in F6Publishing: 289] [Article Influence: 18.4] [Reference Citation Analysis]
295 Chen M, Du Q, Zhang HY, Wang X, Liang Z. High-throughput screening using siRNA (RNAi) libraries. Expert Rev Mol Diagn 2007;7:281-91. [PMID: 17489735 DOI: 10.1586/14737159.7.3.281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
296 Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Curr Protoc Nucleic Acid Chem 2009;Chapter 16:Unit 16.3. [PMID: 20013783 DOI: 10.1002/0471142700.nc1603s39] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
297 Cheever A, Blackwell E, Ceman S. Fragile X protein family member FXR1P is regulated by microRNAs. RNA 2010;16:1530-9. [PMID: 20519410 DOI: 10.1261/rna.2022210] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
298 Liu Q, Zhou H, Zhu R, Xu Y, Cao Z. Reconsideration of in silico siRNA design from a perspective of heterogeneous data integration: problems and solutions. Brief Bioinform 2014;15:292-305. [PMID: 23275634 DOI: 10.1093/bib/bbs073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
299 Kosovrasti VY, Lukashev D, Nechev LV, Amiji MM. Novel RNA interference-based therapies for sepsis. Expert Opin Biol Ther 2014;14:419-35. [PMID: 24397825 DOI: 10.1517/14712598.2014.875524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
300 Bhardwaj V. Villain of Molecular Biology: Why are we not reproducible in research? F1000Res 2015;4:438. [PMID: 26339478 DOI: 10.12688/f1000research.6854.1] [Reference Citation Analysis]
301 Liu F, Wang C, Gao Y, Li X, Tian F, Zhang Y, Fu M, Li P, Wang Y, Wang F. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs. Mol Diagn Ther 2018;22:551-69. [PMID: 29926308 DOI: 10.1007/s40291-018-0338-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
302 Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19. [PMID: 19025401 DOI: 10.1089/oli.2008.0164] [Cited by in Crossref: 325] [Cited by in F6Publishing: 303] [Article Influence: 25.0] [Reference Citation Analysis]
303 Friedman RC, Burge CB. MicroRNA target finding by comparative genomics. Methods Mol Biol 2014;1097:457-76. [PMID: 24639172 DOI: 10.1007/978-1-62703-709-9_21] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
304 Boudreau RL, Davidson BL. Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol 2012;507:275-96. [PMID: 22365779 DOI: 10.1016/B978-0-12-386509-0.00014-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
305 Giuliano CJ, Lin A, Smith JC, Palladino AC, Sheltzer JM. MELK expression correlates with tumor mitotic activity but is not required for cancer growth. Elife 2018;7:e32838. [PMID: 29417930 DOI: 10.7554/eLife.32838] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
306 Swedlow JR. Innovation in biological microscopy: current status and future directions. Bioessays 2012;34:333-40. [PMID: 22408015 DOI: 10.1002/bies.201100168] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
307 Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007;117:3623-32. [PMID: 18060020 DOI: 10.1172/JCI33494] [Cited by in Crossref: 339] [Cited by in F6Publishing: 140] [Article Influence: 24.2] [Reference Citation Analysis]
308 Wang J, Mi P, Lin G, Wáng YX, Liu G, Chen X. Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Deliv Rev 2016;104:44-60. [PMID: 26805788 DOI: 10.1016/j.addr.2016.01.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
309 Blighe K, DeDionisio L, Christie KA, Chawes B, Shareef S, Kakouli-Duarte T, Chao-Shern C, Harding V, Kelly RS, Castellano L, Stebbing J, Lasky-Su JA, Nesbit MA, Moore CBT. Gene editing in the context of an increasingly complex genome. BMC Genomics 2018;19:595. [PMID: 30086710 DOI: 10.1186/s12864-018-4963-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Cheng G, Zhu L, Mahato RI. Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol Pharm 2008;5:1093-102. [PMID: 18828606 DOI: 10.1021/mp800093f] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
311 Gong W, Ren Y, Zhou H, Wang Y, Kang S, Li T. siDRM: an effective and generally applicable online siRNA design tool. Bioinformatics 2008;24:2405-6. [PMID: 18718944 DOI: 10.1093/bioinformatics/btn442] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
312 Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59:75-86. [PMID: 17449137 DOI: 10.1016/j.addr.2007.03.005] [Cited by in Crossref: 589] [Cited by in F6Publishing: 552] [Article Influence: 39.3] [Reference Citation Analysis]
313 Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, Faghihi MA, Khalil AM, Lu L, Paroo Z, Chan AW, Shi Z, Liu Q, Wahlestedt C, He C, Jin P. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008;26:933-40. [PMID: 18641635 DOI: 10.1038/nbt.1481] [Cited by in Crossref: 161] [Cited by in F6Publishing: 156] [Article Influence: 11.5] [Reference Citation Analysis]
314 Patel M, Peter ME. Identification of DISE-inducing shRNAs by monitoring cellular responses. Cell Cycle 2018;17:506-14. [PMID: 29092660 DOI: 10.1080/15384101.2017.1383576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
315 Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceuticals (Basel) 2020;13:E294. [PMID: 33036435 DOI: 10.3390/ph13100294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
316 Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers. Pharmaceutics 2018;10:E65. [PMID: 29861465 DOI: 10.3390/pharmaceutics10020065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
317 Sikarwar AP, Reddy KV. siRNA-mediated silencing of c-kit in mouse primary spermatogonial cells induces cell cycle arrest. Oligonucleotides 2008;18:145-60. [PMID: 18637732 DOI: 10.1089/oli.2008.0108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
318 Hagen J, Young ND, Every AL, Pagel CN, Schnoeller C, Scheerlinck JP, Gasser RB, Kalinna BH. Omega-1 knockdown in Schistosoma mansoni eggs by lentivirus transduction reduces granuloma size in vivo. Nat Commun 2014;5:5375. [PMID: 25400038 DOI: 10.1038/ncomms6375] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
319 Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D, Karpilow J, Khvorova A. A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2007;2:2068-78. [PMID: 17853862 DOI: 10.1038/nprot.2007.278] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
320 Sahin O, Löbke C, Korf U, Appelhans H, Sültmann H, Poustka A, Wiemann S, Arlt D. Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci U S A 2007;104:6579-84. [PMID: 17420474 DOI: 10.1073/pnas.0606827104] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
321 Reynolds SE, Eleftherianos I. RNAI AND THE INSECT IMMUNE SYSTEM. Insect Immunology. Elsevier; 2008. pp. 295-330. [DOI: 10.1016/b978-012373976-6.50014-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
322 Das S, Ghosal S, Chakrabarti J, Kozak K. SeedSeq: off-target transcriptome database. Biomed Res Int 2013;2013:905429. [PMID: 24069606 DOI: 10.1155/2013/905429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
323 Liang X, Li D, Leng S, Zhu X. RNA-based pharmacotherapy for tumors: From bench to clinic and back. Biomed Pharmacother 2020;125:109997. [PMID: 32062550 DOI: 10.1016/j.biopha.2020.109997] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
324 Heigwer F, Port F, Boutros M. RNA Interference (RNAi) Screening in Drosophila. Genetics 2018;208:853-74. [PMID: 29487145 DOI: 10.1534/genetics.117.300077] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 11.8] [Reference Citation Analysis]
325 Tai W. Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery. Molecules 2019;24:E2211. [PMID: 31200490 DOI: 10.3390/molecules24122211] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
326 Jeong JH, Mok H, Oh Y, Park TG. siRNA Conjugate Delivery Systems. Bioconjugate Chem 2009;20:5-14. [DOI: 10.1021/bc800278e] [Cited by in Crossref: 249] [Cited by in F6Publishing: 223] [Article Influence: 17.8] [Reference Citation Analysis]
327 Lozada-Delgado EL, Grafals-Ruiz N, Vivas-Mejía PE. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Life Sci 2017;188:26-36. [PMID: 28864225 DOI: 10.1016/j.lfs.2017.08.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
328 Liu JR, Deng ZH, Zhu XJ, Zeng YR, Guan XX, Li JH. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. Biomed Res Int 2021;2021:9924314. [PMID: 34368359 DOI: 10.1155/2021/9924314] [Reference Citation Analysis]
329 Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329-340. [PMID: 21499294 DOI: 10.1038/nrg2968] [Cited by in Crossref: 528] [Cited by in F6Publishing: 479] [Article Influence: 48.0] [Reference Citation Analysis]
330 Yau EH, Taggart RT, Zuber M, Trujillo AJ, Fayazi ZS, Butler MC, Sheflin LG, Breen JB, Yu D, Sullivan JM. Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics. Transl Vis Sci Technol 2019;8:28. [PMID: 31853424 DOI: 10.1167/tvst.8.6.28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
331 Gaillochet C, Develtere W, Jacobs TB. CRISPR screens in plants: approaches, guidelines, and future prospects. Plant Cell 2021;33:794-813. [PMID: 33823021 DOI: 10.1093/plcell/koab099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
332 Zhao L, Imperiale MJ. Identification of Rab18 as an Essential Host Factor for BK Polyomavirus Infection Using a Whole-Genome RNA Interference Screen. mSphere 2017;2:e00291-17. [PMID: 28815213 DOI: 10.1128/mSphereDirect.00291-17] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
333 Lee YY, Yarmishyn AA, Wang ML, Chen HY, Chiou SH, Yang YP, Lin CF, Huang PI, Chen YW, Ma HI, Chen MT. MicroRNA-142-3p is involved in regulation of MGMT expression in glioblastoma cells. Cancer Manag Res 2018;10:775-85. [PMID: 29695934 DOI: 10.2147/CMAR.S157261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
334 Caffrey DR, Zhao J, Song Z, Schaffer ME, Haney SA, Subramanian RR, Seymour AB, Hughes JD. siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One 2011;6:e21503. [PMID: 21750714 DOI: 10.1371/journal.pone.0021503] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
335 Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol 2018;46:274-83. [PMID: 28423924 DOI: 10.1080/21691401.2017.1307210] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 19.2] [Reference Citation Analysis]
336 Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA 2012;18:945-57. [PMID: 22461413 DOI: 10.1261/rna.032938.112] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
337 Bickle M. The beautiful cell: high-content screening in drug discovery. Anal Bioanal Chem 2010;398:219-26. [DOI: 10.1007/s00216-010-3788-3] [Cited by in Crossref: 127] [Cited by in F6Publishing: 98] [Article Influence: 10.6] [Reference Citation Analysis]
338 deRonde BM, Torres JA, Minter LM, Tew GN. Development of Guanidinium-Rich Protein Mimics for Efficient siRNA Delivery into Human T Cells. Biomacromolecules 2015;16:3172-9. [PMID: 26324222 DOI: 10.1021/acs.biomac.5b00795] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
339 Caobi A, Dutta RK, Garbinski LD, Esteban-Lopez M, Ceyhan Y, Andre M, Manevski M, Ojha CR, Lapierre J, Tiwari S, Parira T, El-Hage N. The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy. Aging Dis 2020;11:895-915. [PMID: 32765953 DOI: 10.14336/AD.2019.0927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Sachdeva M, Sachdeva N, Pal M, Gupta N, Khan IA, Majumdar M, Tiwari A. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther 2015;22:509-17. [PMID: 26494554 DOI: 10.1038/cgt.2015.54] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
341 Harris EA, Buzina A, Moffat J, Mcmillen DR. Design and Experimental Validation of Small Activating RNAs Targeting an Exogenous Promoter in Human Cells. ACS Synth Biol 2017;6:628-37. [DOI: 10.1021/acssynbio.6b00125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
342 Dixit R, Iciek LA, Mckeever K, Ryan PC. Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models. Expert Opinion on Drug Discovery 2009;5:79-94. [DOI: 10.1517/17460440903443410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
343 Abdelmaksoud HE, Yau EH, Zuker M, Sullivan JM. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy. Exp Eye Res 2009;88:859-79. [PMID: 19094986 DOI: 10.1016/j.exer.2008.11.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
344 Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplen NJ, Ried T. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2011;128:1069-79. [PMID: 20473941 DOI: 10.1002/ijc.25453] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
345 Nóbrega C, Codêsso JM, Mendonça L, Pereira de Almeida L. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3. Hum Gene Ther 2019;30:841-54. [PMID: 30760052 DOI: 10.1089/hum.2018.157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
346 Crnković-mertens I, Bulkescher J, Mensger C, Hoppe-seyler F, Hoppe-seyler K. Isolation of peptides blocking the function of anti-apoptotic Livin protein. Cell Mol Life Sci 2010;67:1895-905. [DOI: 10.1007/s00018-010-0300-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
347 Houben R, Schmid CP, Maier M, Wobser M, Motschenbacher S, Becker JC, Vetter-Kauczok CS, Weyandt G, Hesbacher S, Haferkamp S. p53 regulation by TRP2 is not pervasive in melanoma. PLoS One 2014;9:e87440. [PMID: 24475287 DOI: 10.1371/journal.pone.0087440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
348 Shariat N, Holladay CD, Cleary RK, Phillips JA 3rd, Patton JG. Isolated growth hormone deficiency type II caused by a point mutation that alters both splice site strength and splicing enhancer function. Clin Genet 2008;74:539-45. [PMID: 18554279 DOI: 10.1111/j.1399-0004.2008.01042.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
349 Brackney DE, Schirtzinger EE, Harrison TD, Ebel GD, Hanley KA. Modulation of flavivirus population diversity by RNA interference. J Virol 2015;89:4035-9. [PMID: 25631077 DOI: 10.1128/JVI.02612-14] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
350 Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009;61:721-31. [PMID: 19328215 DOI: 10.1016/j.addr.2009.03.003] [Cited by in Crossref: 340] [Cited by in F6Publishing: 321] [Article Influence: 26.2] [Reference Citation Analysis]
351 Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-184. [PMID: 17304245 DOI: 10.1038/nrg2006] [Cited by in Crossref: 743] [Cited by in F6Publishing: 677] [Article Influence: 49.5] [Reference Citation Analysis]
352 Martínez T, Jiménez AI, Pañeda C. Short-interference RNAs: becoming medicines. EXCLI J 2015;14:714-46. [PMID: 26648823 DOI: 10.17179/excli2015-297] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
353 Shkurnikov M, Nikulin S, Nersisyan S, Poloznikov A, Zaidi S, Baranova A, Schumacher U, Wicklein D, Tonevitsky A. LAMA4-Regulating miR-4274 and Its Host Gene SORCS2 Play a Role in IGFBP6-Dependent Effects on Phenotype of Basal-Like Breast Cancer. Front Mol Biosci 2019;6:122. [PMID: 31781574 DOI: 10.3389/fmolb.2019.00122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
354 Ulman A, Skrzypek K, Konieczny P, Mussolino C, Cathomen T, Majka M. Genome Editing of the SNAI1 Gene in Rhabdomyosarcoma: A Novel Model for Studies of Its Role. Cells 2020;9:E1095. [PMID: 32354171 DOI: 10.3390/cells9051095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
355 Berger KL, Randall G. Possibilities for RNA interference in developing hepatitis C virus therapeutics. Viruses 2010;2:1647-65. [PMID: 21994699 DOI: 10.3390/v2081647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
356 Singh S, Wu X, Ljosa V, Bray MA, Piccioni F, Root DE, Doench JG, Boehm JS, Carpenter AE. Morphological Profiles of RNAi-Induced Gene Knockdown Are Highly Reproducible but Dominated by Seed Effects. PLoS One 2015;10:e0131370. [PMID: 26197079 DOI: 10.1371/journal.pone.0131370] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
357 Wawrzyniak D, Grabowska M, Głodowicz P, Kuczyński K, Kuczyńska B, Fedoruk-Wyszomirska A, Rolle K. Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment. PLoS One 2020;15:e0237889. [PMID: 32817625 DOI: 10.1371/journal.pone.0237889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
358 Neumeier J, Meister G. siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects. Front Plant Sci 2020;11:526455. [PMID: 33584737 DOI: 10.3389/fpls.2020.526455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
359 Tiemann K, Höhn B, Ehsani A, Forman SJ, Rossi JJ, Saetrom P. Dual-targeting siRNAs. RNA 2010;16:1275-84. [PMID: 20410240 DOI: 10.1261/rna.2005710] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
360 Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci. 2008;9:978-999. [PMID: 19325841 DOI: 10.3390/ijms9060978] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 7.4] [Reference Citation Analysis]
361 Sætrom P, Snøve O, Rossi JJ. Epigenetics and MicroRNAs. Pediatr Res 2007;61:17R-23R. [DOI: 10.1203/pdr.0b013e318045760e] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
362 Hasegawa Y, Mao W, Saha S, Gunner G, Kolpakova J, Martin GE, Futai K. Luciferase shRNA Presents off-Target Effects on Voltage-Gated Ion Channels in Mouse Hippocampal Pyramidal Neurons. eNeuro 2017;4:ENEURO. [PMID: 29034317 DOI: 10.1523/ENEURO.0186-17.2017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
363 Seinen E, Burgerhof JG, Jansen RC, Sibon OC. RNAi experiments in D. melanogaster: solutions to the overlooked problem of off-targets shared by independent dsRNAs. PLoS One 2010;5:e13119. [PMID: 20957038 DOI: 10.1371/journal.pone.0013119] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
364 Grimard V, Massier J, Richter D, Schwudke D, Kalaidzidis Y, Fava E, Hermetter A, Thiele C. siRNA screening reveals JNK2 as an evolutionary conserved regulator of triglyceride homeostasis. Journal of Lipid Research 2008;49:2427-40. [DOI: 10.1194/jlr.m800168-jlr200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
365 Schmich F, Szczurek E, Kreibich S, Dilling S, Andritschke D, Casanova A, Low SH, Eicher S, Muntwiler S, Emmenlauer M, Rämö P, Conde-Alvarez R, von Mering C, Hardt WD, Dehio C, Beerenwinkel N. gespeR: a statistical model for deconvoluting off-target-confounded RNA interference screens. Genome Biol 2015;16:220. [PMID: 26445817 DOI: 10.1186/s13059-015-0783-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
366 Das T, Das TK, Khodarkovskaya A, Dash S. Non-coding RNAs and their bioengineering applications for neurological diseases. Bioengineered 2021. [PMID: 34756133 DOI: 10.1080/21655979.2021.2003667] [Reference Citation Analysis]
367 Breda J, Rzepiela AJ, Gumienny R, van Nimwegen E, Zavolan M. Quantifying the strength of miRNA–target interactions. Methods 2015;85:90-9. [DOI: 10.1016/j.ymeth.2015.04.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
368 Stobart MJ, Simon SLR, Plews M, Lamoureux L, Knox JD. Efficient Knockdown of Human prnp mRNA Expression Levels Using Hybrid Hammerhead Ribozymes. Journal of Toxicology and Environmental Health, Part A 2009;72:1034-9. [DOI: 10.1080/15287390903084314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
369 Kapilov-Buchman Y, Lellouche E, Michaeli S, Lellouche JP. Unique Surface Modification of Silica Nanoparticles with Polyethylenimine (PEI) for siRNA Delivery Using Cerium Cation Coordination Chemistry. Bioconjug Chem 2015;26:880-9. [PMID: 25830668 DOI: 10.1021/acs.bioconjchem.5b00100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
370 Jackson AL, Mao M, Kobayashi S, Ward T, Biery M, Dai H, Bartz SR, Linsley PS. Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor. Cancer Inform 2008;6:147-64. [PMID: 19259408 DOI: 10.4137/cin.s609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
371 Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4. [PMID: 26267216 DOI: 10.7554/elife.05005] [Cited by in Crossref: 3002] [Cited by in F6Publishing: 2239] [Article Influence: 428.9] [Reference Citation Analysis]
372 Fewell GD, Schmitt K. Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discovery Today 2006;11:975-82. [DOI: 10.1016/j.drudis.2006.09.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
373 Zagalak JA, Menzi M, Schmich F, Jahns H, Dogar AM, Wullschleger F, Towbin H, Hall J. Properties of short double-stranded RNAs carrying randomized base pairs: toward better controls for RNAi experiments. RNA 2015;21:2132-42. [PMID: 26516083 DOI: 10.1261/rna.053637.115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
374 Farazi TA, Juranek SA, Tuschl T. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development 2008;135:1201-14. [PMID: 18287206 DOI: 10.1242/dev.005629] [Cited by in Crossref: 283] [Cited by in F6Publishing: 279] [Article Influence: 20.2] [Reference Citation Analysis]
375 Svoboda P. Key Mechanistic Principles and Considerations Concerning RNA Interference. Front Plant Sci 2020;11:1237. [PMID: 32903622 DOI: 10.3389/fpls.2020.01237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
376 Bramsen JB, Kjems J. Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet 2012;3:154. [PMID: 22934103 DOI: 10.3389/fgene.2012.00154] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
377 Lloret-Llinares M, Jensen TH. Global Identification of Human Exosome Substrates Using RNA Interference and RNA Sequencing. Methods Mol Biol 2020;2062:127-45. [PMID: 31768975 DOI: 10.1007/978-1-4939-9822-7_7] [Reference Citation Analysis]
378 Thompson AJ, Patel K. Antisense inhibitors, ribozymes, and siRNAs. Clin Liver Dis 2009;13:375-90. [PMID: 19628155 DOI: 10.1016/j.cld.2009.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
379 Brackett K, Mungale A, Lopez-Isidro M, Proctor DA, Najarro G, Arias C. CRISPR Interference Efficiently Silences Latent and Lytic Viral Genes in Kaposi's Sarcoma-Associated Herpesvirus-Infected Cells. Viruses 2021;13:783. [PMID: 33924938 DOI: 10.3390/v13050783] [Reference Citation Analysis]
380 Kini HK, Walton SP. Effect of siRNA terminal mismatches on TRBP and Dicer binding and silencing efficacy. FEBS J 2009;276:6576-85. [PMID: 19811537 DOI: 10.1111/j.1742-4658.2009.07364.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
381 Ku SH, Jo SD, Lee YK, Kim K, Kim SH. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev 2016;104:16-28. [PMID: 26549145 DOI: 10.1016/j.addr.2015.10.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 9.1] [Reference Citation Analysis]
382 Mohanta TK, Bashir T, Hashem A, Abd Allah EF, Bae H. Genome Editing Tools in Plants. Genes (Basel) 2017;8:E399. [PMID: 29257124 DOI: 10.3390/genes8120399] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
383 Potts MB, Kim HS, Fisher KW, Hu Y, Carrasco YP, Bulut GB, Ou YH, Herrera-Herrera ML, Cubillos F, Mendiratta S, Xiao G, Hofree M, Ideker T, Xie Y, Huang LJ, Lewis RE, MacMillan JB, White MA. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products. Sci Signal 2013;6:ra90. [PMID: 24129700 DOI: 10.1126/scisignal.2004657] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
384 Kleefeldt JM, Pozarska A, Nardiello C, Pfeffer T, Vadász I, Herold S, Seeger W, Morty RE. Commercially available transfection reagents and negative control siRNA are not inert. Anal Biochem 2020;606:113828. [PMID: 32745542 DOI: 10.1016/j.ab.2020.113828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
385 Chorn G, Zhao L, Sachs AB, Flanagan WM, Lim LP. Persistence of seed-based activity following segmentation of a microRNA guide strand. RNA 2010;16:2336-40. [PMID: 20971811 DOI: 10.1261/rna.2296210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
386 Martínez MA. Progress in the therapeutic applications of siRNAs against HIV-1. Methods Mol Biol 2009;487:343-68. [PMID: 19301656 DOI: 10.1007/978-1-60327-547-7_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
387 Stefani G. Roles of microRNAs and their targets in cancer. Expert Opinion on Biological Therapy 2007;7:1833-40. [DOI: 10.1517/14712598.7.12.1833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
388 Joseph TT, Osman R. Convergent transmission of RNAi guide-target mismatch information across Argonaute internal allosteric network. PLoS Comput Biol 2012;8:e1002693. [PMID: 23028290 DOI: 10.1371/journal.pcbi.1002693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
389 Hartenian E, Doench JG. Genetic screens and functional genomics using CRISPR/Cas9 technology. FEBS J 2015;282:1383-93. [DOI: 10.1111/febs.13248] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
390 Nielsen C, Kjems J, Sørensen KR, Engelholm LH, Behrendt N. Advances in targeted delivery of small interfering RNA using simple bioconjugates. Expert Opin Drug Deliv 2014;11:791-822. [PMID: 24669756 DOI: 10.1517/17425247.2014.896898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
391 Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008;36:2136-51. [PMID: 18267968 DOI: 10.1093/nar/gkn042] [Cited by in F6Publishing: 109] [Reference Citation Analysis]
392 Shao DD, Tsherniak A, Gopal S, Weir BA, Tamayo P, Stransky N, Schumacher SE, Zack TI, Beroukhim R, Garraway LA, Margolin AA, Root DE, Hahn WC, Mesirov JP. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 2013;23:665-78. [PMID: 23269662 DOI: 10.1101/gr.143586.112] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 9.6] [Reference Citation Analysis]
393 Juliano R. Challenges to macromolecular drug delivery. Biochem Soc Trans 2007;35:41-3. [PMID: 17233596 DOI: 10.1042/BST0350041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
394 Mazda M, Nishi K, Naito Y, Ui-Tei K. E-cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing. PLoS One 2011;6:e28688. [PMID: 22205962 DOI: 10.1371/journal.pone.0028688] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
395 Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, Jackson AL, Carleton M, Lim L. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007;27:2240-2252. [PMID: 17242205 DOI: 10.1128/mcb.02005-06] [Cited by in Crossref: 382] [Cited by in F6Publishing: 270] [Article Influence: 25.5] [Reference Citation Analysis]
396 J. Russell S, Whye Peng K. GENE THERAPY. Pharmacology and Therapeutics. Elsevier; 2009. pp. 1295-316. [DOI: 10.1016/b978-1-4160-3291-5.50097-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
397 Johnson E, Chase K, McGowan S, Mondo E, Pfister E, Mick E, Friedline RH, Kim JK, Sapp E, DiFiglia M, Aronin N. Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model. J Huntingtons Dis 2015;4:219-29. [PMID: 26444021 DOI: 10.3233/JHD-150163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
398 Heestermans M, de Jong A, van Tilburg S, Reitsma PH, Versteeg HH, Spronk HM, van Vlijmen BJ. Use of “C9/11 Mismatch” Control siRNA Reveals Sequence-Related Off-Target Effect on Coagulation of an siRNA Targeting Mouse Coagulation Factor XII. Nucleic Acid Therapeutics 2019;29:218-23. [DOI: 10.1089/nat.2018.0767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
399 He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther 2021;6:185. [PMID: 34016945 DOI: 10.1038/s41392-021-00569-5] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
400 Mahas A, Neal Stewart C, Mahfouz MM. Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation. Biotechnology Advances 2018;36:295-310. [DOI: 10.1016/j.biotechadv.2017.11.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
401 Jagannath A, Wood MJ. Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol Biol Cell 2009;20:521-9. [PMID: 18946079 DOI: 10.1091/mbc.e08-08-0796] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
402 Shen H, McHale CM, Smith MT, Zhang L. Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9. Mutat Res Rev Mutat Res 2015;764:31-42. [PMID: 26041264 DOI: 10.1016/j.mrrev.2015.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
403 Andachi Y. A novel biochemical method to identify target genes of individual microRNAs: identification of a new Caenorhabditis elegans let-7 target. RNA 2008;14:2440-51. [PMID: 18824511 DOI: 10.1261/rna.1139508] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
404 Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011;300:10-19. [PMID: 20965651 DOI: 10.1016/j.canlet.2010.09.019] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 10.5] [Reference Citation Analysis]
405 Ufaz S, Balter A, Tzror C, Einbender S, Koshet O, Shainsky-roitman J, Yaari Z, Schroeder A. Anti-viral RNAi nanoparticles protect shrimp against white spot disease. Mol Syst Des Eng 2018;3:38-48. [DOI: 10.1039/c7me00092h] [Cited by in Crossref: 11] [Article Influence: 2.8] [Reference Citation Analysis]
406 An DS, Donahue RE, Kamata M, Poon B, Metzger M, Mao SH, Bonifacino A, Krouse AE, Darlix JL, Baltimore D, Qin FX, Chen IS. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A 2007;104:13110-5. [PMID: 17670939 DOI: 10.1073/pnas.0705474104] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 8.1] [Reference Citation Analysis]
407 Maida Y, Kyo S, Lassmann T, Hayashizaki Y, Masutomi K. Off-target effect of endogenous siRNA derived from RMRP in human cells. Int J Mol Sci 2013;14:9305-18. [PMID: 23629666 DOI: 10.3390/ijms14059305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
408 Buchholz F, Kittler R, Slabicki M, Theis M. Enzymatically prepared RNAi libraries. Nat Methods 2006;3:696-700. [PMID: 16929314 DOI: 10.1038/nmeth912] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
409 Bhinder B, Shum D, Li M, Ibáñez G, Vlassov AV, Magdaleno S, Djaballah H. Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens. PLoS One 2014;9:e100676. [PMID: 24987961 DOI: 10.1371/journal.pone.0100676] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
410 Janas MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, Keirstead ND, Warner G. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies. Toxicol Pathol 2018;46:735-45. [PMID: 30139307 DOI: 10.1177/0192623318792537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
411 Dykxhoorn DM. RNA interference as an anticancer therapy: a patent perspective. Expert Opinion on Therapeutic Patents 2009;19:475-91. [DOI: 10.1517/13543770902838008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
412 Snøve O, Rossi JJ. Expressing short hairpin RNAs in vivo. Nat Methods 2006;3:689-95. [DOI: 10.1038/nmeth927] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
413 Angermeyer S, Hesbacher S, Becker JC, Schrama D, Houben R. Merkel cell polyomavirus-positive Merkel cell carcinoma cells do not require expression of the viral small T antigen. J Invest Dermatol 2013;133:2059-64. [PMID: 23439392 DOI: 10.1038/jid.2013.82] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
414 Li J, Levin DS, Kim AJ, Pappas SS, Dauer WT. TorsinA restoration in a mouse model identifies a critical therapeutic window for DYT1 dystonia. J Clin Invest 2021;131:139606. [PMID: 33529159 DOI: 10.1172/JCI139606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
415 Jarosch A, Moritz RFA. RNA interference in honeybees: off-target effects caused by dsRNA. Apidologie 2012;43:128-38. [DOI: 10.1007/s13592-011-0092-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
416 Parker JS, Parizotto EA, Wang M, Roe SM, Barford D. Enhancement of the seed-target recognition step in RNA silencing by a PIWI/MID domain protein. Mol Cell 2009;33:204-14. [PMID: 19187762 DOI: 10.1016/j.molcel.2008.12.012] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
417 Traxler EA, Thom CS, Yao Y, Paralkar V, Weiss MJ. Nonspecific inhibition of erythropoiesis by short hairpin RNAs. Blood 2018;131:2733-6. [PMID: 29728407 DOI: 10.1182/blood-2018-03-841304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
418 Yang C, Zhang C, Zhao Z, Zhu T, Yang B. Fighting against kidney diseases with small interfering RNA: opportunities and challenges. J Transl Med 2015;13:39. [PMID: 25637948 DOI: 10.1186/s12967-015-0387-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
419 Ruangsri S, Lin A, Mulpuri Y, Lee K, Spigelman I, Nishimura I. Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats. J Biol Chem 2011;286:39836-47. [PMID: 21965668 DOI: 10.1074/jbc.M111.261701] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
420 Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006;2:e140. [PMID: 16965178 DOI: 10.1371/journal.pgen.0020140] [Cited by in Crossref: 189] [Cited by in F6Publishing: 175] [Article Influence: 11.8] [Reference Citation Analysis]
421 Paces J, Nic M, Novotny T, Svoboda P. Literature review of baseline information to support the risk assessment of RNAi‐based GM plants. EFS3 2017;14. [DOI: 10.2903/sp.efsa.2017.en-1246] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
422 Alagia A, Eritja R. siRNA and RNAi optimization. Wiley Interdiscip Rev RNA 2016;7:316-29. [PMID: 26840434 DOI: 10.1002/wrna.1337] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
423 Peterson JM, Seldin MM, Wei Z, Aja S, Wong GW. CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol 2013;305:G214-24. [PMID: 23744740 DOI: 10.1152/ajpgi.00102.2013] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.9] [Reference Citation Analysis]
424 Ui-Tei K. Optimal choice of functional and off-target effect-reduced siRNAs for RNAi therapeutics. Front Genet 2013;4:107. [PMID: 23781232 DOI: 10.3389/fgene.2013.00107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
425 Tripp RA, Tompkins SM. Therapeutic Applications of RNAi for Silencing Virus Replication. In: Rondinone CM, Reidhaar-olson JF, editors. Therapeutic Applications of RNAi. Totowa: Humana Press; 2009. pp. 43-61. [DOI: 10.1007/978-1-60327-295-7_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
426 Wang X, Wang X, Varma RK, Beauchamp L, Magdaleno S, Sendera TJ. Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res 2009;37:e152. [PMID: 19846596 DOI: 10.1093/nar/gkp864] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
427 Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67. [PMID: 21160526 DOI: 10.1038/nrc2966] [Cited by in Crossref: 551] [Cited by in F6Publishing: 522] [Article Influence: 45.9] [Reference Citation Analysis]
428 Liu YP, Gruber J, Haasnoot J, Konstantinova P, Berkhout B. RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences. Nucleic Acids Res. 2009;37:6194-6204. [PMID: 19656954 DOI: 10.1093/nar/gkp644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
429 Fujimoto H, Kato K, Iwata H. Use of microarrays in transfection of mammalian cells with dicer-digested small interfering RNAs. Analytical Biochemistry 2008;374:417-22. [DOI: 10.1016/j.ab.2007.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
430 Sætrom P. Designing dual-targeting siRNA duplexes having two active strands that combine siRNA and microRNA-like targeting. Methods Mol Biol 2013;942:169-77. [PMID: 23027051 DOI: 10.1007/978-1-62703-119-6_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
431 Angart PA, Carlson RJ, Adu-Berchie K, Walton SP. Terminal Duplex Stability and Nucleotide Identity Differentially Control siRNA Loading and Activity in RNA Interference. Nucleic Acid Ther 2016;26:309-17. [PMID: 27399870 DOI: 10.1089/nat.2016.0612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
432 Nandety RS, Kuo YW, Nouri S, Falk BW. Emerging strategies for RNA interference (RNAi) applications in insects. Bioengineered 2015;6:8-19. [PMID: 25424593 DOI: 10.4161/21655979.2014.979701] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
433 Mukherjee A, MacDonald KD, Kim J, Henderson MI, Eygeris Y, Sahay G. Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models. Sci Adv 2020;6:eabc5911. [PMID: 33208364 DOI: 10.1126/sciadv.abc5911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
434 Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA interference and cancer therapy. Pharm Res 2011;28:2983-95. [PMID: 22009588 DOI: 10.1007/s11095-011-0604-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 8.7] [Reference Citation Analysis]
435 Ghildiyal M, Xu J, Seitz H, Weng Z, Zamore PD. Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway. RNA 2010;16:43-56. [PMID: 19917635 DOI: 10.1261/rna.1972910] [Cited by in Crossref: 240] [Cited by in F6Publishing: 230] [Article Influence: 18.5] [Reference Citation Analysis]
436 Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19:937-954. [PMID: 22921062 DOI: 10.1016/j.chembiol.2012.07.011] [Cited by in Crossref: 391] [Cited by in F6Publishing: 352] [Article Influence: 39.1] [Reference Citation Analysis]
437 Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015;87:108-19. [PMID: 25666164 DOI: 10.1016/j.addr.2015.01.007] [Cited by in Crossref: 280] [Cited by in F6Publishing: 256] [Article Influence: 40.0] [Reference Citation Analysis]
438 Seraj S, Cho YJ, Lee J, Ahn HJ. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects. Biochemical Pharmacology 2020;171:113735. [DOI: 10.1016/j.bcp.2019.113735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
439 Ki KH, Park DY, Lee SH, Kim NY, Choi BM, Noh GJ. The optimal concentration of siRNA for gene silencing in primary cultured astrocytes and microglial cells of rats. Korean J Anesthesiol 2010;59:403-10. [PMID: 21253378 DOI: 10.4097/kjae.2010.59.6.403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
440 Vinther J, Hedegaard MM, Gardner PP, Andersen JS, Arctander P. Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res 2006;34:e107. [PMID: 16945957 DOI: 10.1093/nar/gkl590] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 5.9] [Reference Citation Analysis]
441 Flynt AS, Lai EC. RNAi in Xenopus: look before you leap. Genes Dev 2011;25:1105-8. [PMID: 21632820 DOI: 10.1101/gad.2062911] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012;7:3637-57. [PMID: 22915840 DOI: 10.2147/IJN.S23696] [Cited by in Crossref: 28] [Cited by in F6Publishing: 66] [Article Influence: 2.8] [Reference Citation Analysis]
443 Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Ther 2012;20:483-512. [PMID: 22186795 DOI: 10.1038/mt.2011.263] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 15.6] [Reference Citation Analysis]
444 Pandi P, Jain A, Raju S, Khan W. Therapeutic approaches for the delivery of TNF-α siRNA. Ther Deliv 2017;8:343-55. [PMID: 28361614 DOI: 10.4155/tde-2017-0011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
445 Lin A, Giuliano CJ, Sayles NM, Sheltzer JM. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife 2017;6:e24179. [PMID: 28337968 DOI: 10.7554/eLife.24179] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 12.4] [Reference Citation Analysis]
446 Majumdar R, Rajasekaran K, Cary JW. RNA Interference (RNAi) as a Potential Tool for Control of Mycotoxin Contamination in Crop Plants: Concepts and Considerations. Front Plant Sci 2017;8:200. [PMID: 28261252 DOI: 10.3389/fpls.2017.00200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
447 Wang M, Wang D, Zhang X, Wang X, Liu W, Hou X, Huang X, Xie B, Cheng X. Double-stranded RNA-mediated interference of dumpy genes in Bursaphelenchus xylophilus by feeding on filamentous fungal transformants. Int J Parasitol 2016;46:351-60. [PMID: 26953254 DOI: 10.1016/j.ijpara.2016.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
448 Wilson PA, Plucinski M. A simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles. BMC Genomics 2011;12:250. [PMID: 21599879 DOI: 10.1186/1471-2164-12-250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
449 Wang Z, Jay CM, Evans C, Kumar P, Phalon C, Rao DD, Senzer N, Nemunaitis J. Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery. Toxicol Sci 2017;155:400-8. [PMID: 27815492 DOI: 10.1093/toxsci/kfw223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
450 tenOever BR. RNA viruses and the host microRNA machinery. Nat Rev Microbiol. 2013;11:169-180. [PMID: 23411862 DOI: 10.1038/nrmicro2971] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 10.7] [Reference Citation Analysis]
451 Zhiyanov A, Nersisyan S, Tonevitsky A. Hairpin sequence and structure is associated with features of isomiR biogenesis. RNA Biol 2021;:1-9. [PMID: 34286662 DOI: 10.1080/15476286.2021.1952759] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 2011;130:583-605. [PMID: 21537948 DOI: 10.1007/s00439-011-0995-8] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
453 Gonzalez-alegre P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacology & Therapeutics 2007;114:34-55. [DOI: 10.1016/j.pharmthera.2007.01.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
454 Bisset DR, Stepniak-Konieczna EA, Zavaljevski M, Wei J, Carter GT, Weiss MD, Chamberlain JR. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet 2015;24:4971-83. [PMID: 26082468 DOI: 10.1093/hmg/ddv219] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
455 Vickers TA, Lima WF, Wu H, Nichols JG, Linsley PS, Crooke ST. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res 2009;37:6927-41. [PMID: 19767612 DOI: 10.1093/nar/gkp735] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
456 Reshi ML, Wu J, Wang H, Hong J. RNA interference technology used for the study of aquatic virus infections. Fish & Shellfish Immunology 2014;40:14-23. [DOI: 10.1016/j.fsi.2014.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
457 Matveeva O. What parameters to consider and which software tools to use for target selection and molecular design of small interfering RNAs. Methods Mol Biol 2013;942:1-16. [PMID: 23027043 DOI: 10.1007/978-1-62703-119-6_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
458 Wolters NM, MacKeigan JP. From sequence to function: using RNAi to elucidate mechanisms of human disease. Cell Death Differ 2008;15:809-19. [PMID: 18202701 DOI: 10.1038/sj.cdd.4402311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
459 Grimm D. Small silencing RNAs: State-of-the-art. Advanced Drug Delivery Reviews 2009;61:672-703. [DOI: 10.1016/j.addr.2009.05.002] [Cited by in Crossref: 133] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis]
460 Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J. A status report on RNAi therapeutics. Silence 2010;1:14. [PMID: 20615220 DOI: 10.1186/1758-907X-1-14] [Cited by in Crossref: 222] [Cited by in F6Publishing: 101] [Article Influence: 18.5] [Reference Citation Analysis]
461 Kobayashi Y, Miyamoto K, Aida M, Ui-Tei K. Selection of Chemical Modifications in the siRNA Seed Region That Repress Off-Target Effect. Methods Mol Biol 2021;2282:17-30. [PMID: 33928567 DOI: 10.1007/978-1-0716-1298-9_2] [Reference Citation Analysis]
462 Knyazev EN, Nyushko KM, Alekseev BY, Samatov TR, Shkurnikov MY. Suppression of ITGB4 Gene Expression in PC-3 Cells with Short Interfering RNA Induces Changes in the Expression of β-Integrins Associated with RGD-Receptors. Bull Exp Biol Med 2015;159:541-5. [DOI: 10.1007/s10517-015-3011-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
463 Rossi JJ. Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 2008;19:313-7. [PMID: 18363506 DOI: 10.1089/hum.2008.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
464 Ping J, Huang S, Wu J, Bao P, Su T, Gu K, Cai H, Guo X, Lipworth L, Blot WJ, Zheng W, Cai Q, Shu XO. Association between lincRNA expression and overall survival for patients with triple-negative breast cancer. Breast Cancer Res Treat 2021;186:769-77. [PMID: 33247368 DOI: 10.1007/s10549-020-06021-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
465 Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008;12:637-45. [PMID: 18410245 DOI: 10.1517/14728222.12.5.637] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 6.0] [Reference Citation Analysis]
466 Chooi YH, Muria-Gonzalez MJ, Mead OL, Solomon PS. SnPKS19 Encodes the Polyketide Synthase for Alternariol Mycotoxin Biosynthesis in the Wheat Pathogen Parastagonospora nodorum. Appl Environ Microbiol 2015;81:5309-17. [PMID: 26025896 DOI: 10.1128/AEM.00278-15] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
467 Hasson SA, Kane LA, Yamano K, Huang CH, Sliter DA, Buehler E, Wang C, Heman-Ackah SM, Hessa T, Guha R, Martin SE, Youle RJ. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature. 2013;504:291-295. [PMID: 24270810 DOI: 10.1038/nature12748] [Cited by in Crossref: 225] [Cited by in F6Publishing: 201] [Article Influence: 25.0] [Reference Citation Analysis]
468 Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 2007;7:297-304. [PMID: 17189960 DOI: 10.1038/sj.tpj.6500429] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
469 Li C, Zamore PD. RNA Interference and Small RNA Analysis. Cold Spring Harb Protoc 2019;2019:pdb.top097436. [DOI: 10.1101/pdb.top097436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
470 Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 2006;13:849-51. [PMID: 16921378 DOI: 10.1038/nsmb1138] [Cited by in Crossref: 300] [Cited by in F6Publishing: 314] [Article Influence: 18.8] [Reference Citation Analysis]
471 Ding L, Poser I, Paszkowski-Rogacz M, Buchholz F. From RNAi screens to molecular function in embryonic stem cells. Stem Cell Rev Rep 2012;8:32-42. [PMID: 21526416 DOI: 10.1007/s12015-011-9269-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
472 Laganà A, Shasha D, Croce CM. Synthetic RNAs for Gene Regulation: Design Principles and Computational Tools. Front Bioeng Biotechnol 2014;2:65. [PMID: 25566532 DOI: 10.3389/fbioe.2014.00065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
473 Younger ST, Corey DR. The puzzle of RNAs that target gene promoters. Chembiochem 2009;10:1135-9. [PMID: 19301312 DOI: 10.1002/cbic.200900015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
474 Leung AK, Sharp PA. Function and localization of microRNAs in mammalian cells. Cold Spring Harb Symp Quant Biol. 2006;71:29-38. [PMID: 17381277 DOI: 10.1101/sqb.2006.71.049] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
475 Moses J, Goodchild A, Rivory LP. Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA 2010;16:430-41. [PMID: 20026621 DOI: 10.1261/rna.1808510] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
476 Falco G, Lee SL, Stanghellini I, Bassey UC, Hamatani T, Ko MS. Zscan4: a novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells. Dev Biol 2007;307:539-50. [PMID: 17553482 DOI: 10.1016/j.ydbio.2007.05.003] [Cited by in Crossref: 161] [Cited by in F6Publishing: 146] [Article Influence: 10.7] [Reference Citation Analysis]
477 Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions--beyond repression of gene expression. Nat Rev Genet. 2014;15:599-612. [PMID: 25022902 DOI: 10.1038/nrg3765] [Cited by in Crossref: 393] [Cited by in F6Publishing: 375] [Article Influence: 49.1] [Reference Citation Analysis]
478 Liu S, Jaouannet M, Dempsey DA, Imani J, Coustau C, Kogel K. RNA-based technologies for insect control in plant production. Biotechnology Advances 2020;39:107463. [DOI: 10.1016/j.biotechadv.2019.107463] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 24.0] [Reference Citation Analysis]
479 Malhotra M, Toulouse A, Godinho BM, Mc Carthy DJ, Cryan JF, O'Driscoll CM. RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies. Mol Biosyst 2015;11:2635-57. [PMID: 26135606 DOI: 10.1039/c5mb00278h] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
480 Delassus GS, Cho H, Eliceiri GL. New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells. J Cell Physiol 2011;226:3378-84. [PMID: 21344390 DOI: 10.1002/jcp.22694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
481 Forbes TA, Brown BD, Lai C. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol 2021. [PMID: 34022071 DOI: 10.1111/bcp.14925] [Reference Citation Analysis]
482 Brzezinska J, D'Onofrio J, Buff MC, Hean J, Ely A, Marimani M, Arbuthnot P, Engels JW. Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. Bioorg Med Chem 2012;20:1594-606. [PMID: 22264759 DOI: 10.1016/j.bmc.2011.12.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
483 Nguyen QB, Kadotani N, Kasahara S, Tosa Y, Mayama S, Nakayashiki H. Systematic functional analysis of calcium-signalling proteins in the genome of the rice-blast fungus, Magnaporthe oryzae, using a high-throughput RNA-silencing system. Mol Microbiol 2008;68:1348-65. [PMID: 18433453 DOI: 10.1111/j.1365-2958.2008.06242.x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
484 Förstemann K, Horwich MD, Wee L, Tomari Y, Zamore PD. Drosophila microRNAs are sorted into functionally distinct argonaute complexes after production by dicer-1. Cell 2007;130:287-97. [PMID: 17662943 DOI: 10.1016/j.cell.2007.05.056] [Cited by in Crossref: 281] [Cited by in F6Publishing: 283] [Article Influence: 18.7] [Reference Citation Analysis]
485 Hibio N, Hino K, Shimizu E, Nagata Y, Ui-Tei K. Stability of miRNA 5'terminal and seed regions is correlated with experimentally observed miRNA-mediated silencing efficacy. Sci Rep 2012;2:996. [PMID: 23251782 DOI: 10.1038/srep00996] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
486 Sudbery I, Enright AJ, Fraser AG, Dunham I. Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis. BMC Genomics 2010;11:175. [PMID: 20230625 DOI: 10.1186/1471-2164-11-175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
487 Rhoo KH, Granger M, Sur J, Feng C, Gelbard HA, Dewhurst S, Polesskaya O. Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model. PLoS One 2014;9:e108487. [PMID: 25264786 DOI: 10.1371/journal.pone.0108487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
488 McFarland JM, Ho ZV, Kugener G, Dempster JM, Montgomery PG, Bryan JG, Krill-Burger JM, Green TM, Vazquez F, Boehm JS, Golub TR, Hahn WC, Root DE, Tsherniak A. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun 2018;9:4610. [PMID: 30389920 DOI: 10.1038/s41467-018-06916-5] [Cited by in F6Publishing: 102] [Reference Citation Analysis]
489 Hinrichsen I, Ernst BP, Nuber F, Passmann S, Schäfer D, Steinke V, Friedrichs N, Plotz G, Zeuzem S, Brieger A. Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. Mol Cancer 2014;13:11. [PMID: 24456667 DOI: 10.1186/1476-4598-13-11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
490 Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, Lund AH, Vang S, Stribolt K, Madsen MR, Laurberg S, McGuire SE, Ørntoft TF, Andersen CL. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol 2016;10:1266-82. [PMID: 27396952 DOI: 10.1016/j.molonc.2016.06.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 93] [Article Influence: 12.7] [Reference Citation Analysis]
491 Loy RE, Lueck JD, Mostajo-Radji MA, Carrell EM, Dirksen RT. Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy. PLoS One 2012;7:e49757. [PMID: 23152933 DOI: 10.1371/journal.pone.0049757] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
492 Berkhout B, ter Brake O. Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opin Biol Ther 2009;9:161-70. [PMID: 19236246 DOI: 10.1517/14712590802653619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
493 Cao H, Meng X, Wang X, Liang Z. Target-Recognition Mechanism and Specificity of RNA Activation. In: Li L, editor. RNA Activation. Singapore: Springer; 2017. pp. 41-51. [DOI: 10.1007/978-981-10-4310-9_3] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
494 Nejati A, Shahmahmoodi S, Arefian E, Shoja Z, Marashi SM, Tabatabaie H, Mollaei-Kandelous Y, Soleimani M, Nategh R. Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts. Exp Ther Med 2016;11:1833-8. [PMID: 27168813 DOI: 10.3892/etm.2016.3121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
495 Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet. 2007;16 Spec No 1:R106-R113. [PMID: 17613543 DOI: 10.1093/hmg/ddm056] [Cited by in Crossref: 126] [Cited by in F6Publishing: 124] [Article Influence: 8.4] [Reference Citation Analysis]
496 Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57-67. [PMID: 20043028 DOI: 10.1038/nrd3010] [Cited by in Crossref: 635] [Cited by in F6Publishing: 605] [Article Influence: 52.9] [Reference Citation Analysis]
497 Quon K, Kassner PD. RNA interference screening for the discovery of oncology targets. Expert Opinion on Therapeutic Targets 2009;13:1027-35. [DOI: 10.1517/14728220903179338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
498 Carlevaro-Fita J, Johnson R. Global Positioning System: Understanding Long Noncoding RNAs through Subcellular Localization. Mol Cell 2019;73:869-83. [PMID: 30849394 DOI: 10.1016/j.molcel.2019.02.008] [Cited by in Crossref: 96] [Cited by in F6Publishing: 84] [Article Influence: 32.0] [Reference Citation Analysis]
499 Gupta AK, Eshraghi Y, Gliniak C, Gosain AK. Nonviral transfection of mouse calvarial organ in vitro using Accell-modified siRNA. Plast Reconstr Surg 2010;125:494-501. [PMID: 19910849 DOI: 10.1097/PRS.0b013e3181c82df1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
500 Burel SA, Hart CE, Cauntay P, Hsiao J, Machemer T, Katz M, Watt A, Bui HH, Younis H, Sabripour M, Freier SM, Hung G, Dan A, Prakash TP, Seth PP, Swayze EE, Bennett CF, Crooke ST, Henry SP. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res 2016;44:2093-109. [PMID: 26553810 DOI: 10.1093/nar/gkv1210] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 11.7] [Reference Citation Analysis]
501 Haussecker D, Kay MA. RNA interference. Drugging RNAi. Science 2015;347:1069-70. [PMID: 25745148 DOI: 10.1126/science.1252967] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
502 Guo Y, Chen Y, Zhang Y, Zhang Y, Chen L, Mo D. Up-regulated miR-145 expression inhibits porcine preadipocytes differentiation by targeting IRS1. Int J Biol Sci 2012;8:1408-17. [PMID: 23197937 DOI: 10.7150/ijbs.4597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
503 Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjær N, Odadzic D, Smicius R, Wengel SL, Chattopadhyaya J, Engels JW, Herdewijn P, Wengel J, Kjems J. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010;38:5761-73. [PMID: 20453030 DOI: 10.1093/nar/gkq341] [Cited by in Crossref: 121] [Cited by in F6Publishing: 114] [Article Influence: 10.1] [Reference Citation Analysis]
504 Olejniczak M, Urbanek MO, Jaworska E, Witucki L, Szczesniak MW, Makalowska I, Krzyzosiak WJ. Sequence-non-specific effects generated by various types of RNA interference triggers. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2016;1859:306-14. [DOI: 10.1016/j.bbagrm.2015.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
505 Tedeschi L, Lande C, Cecchettini A, Citti L. Hammerhead ribozymes in therapeutic target discovery and validation. Drug Discov Today 2009;14:776-83. [PMID: 19477286 DOI: 10.1016/j.drudis.2009.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
506 Bak RO, Mikkelsen JG. Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci 2010;17:53. [PMID: 20594301 DOI: 10.1186/1423-0127-17-53] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
507 Petrick JS, Brower-Toland B, Jackson AL, Kier LD. Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: a scientific review. Regul Toxicol Pharmacol 2013;66:167-76. [PMID: 23557984 DOI: 10.1016/j.yrtph.2013.03.008] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
508 Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opinion on Drug Delivery 2010;7:859-69. [DOI: 10.1517/17425247.2010.490554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
509 Murray EJ, Burden F, Horscroft N, Smith-Burchnell C, Westby M. Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells. Antimicrob Agents Chemother 2011;55:4311-9. [PMID: 21709085 DOI: 10.1128/AAC.00644-11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
510 Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol 2021;16:630-43. [PMID: 34059811 DOI: 10.1038/s41565-021-00898-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
511 Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC, Gray JW, Chen FF. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014;4:872-92. [PMID: 25057313 DOI: 10.7150/thno.9404] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 16.1] [Reference Citation Analysis]
512 Merry HE, Phelan P, Hwang B, Mulligan MS. Validating the use of short interfering RNA as a novel technique for cell-specific target gene knockdown in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2016;151:499-506. [PMID: 26687890 DOI: 10.1016/j.jtcvs.2015.09.125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
513 Nerlich A, Ruangkiattikul N, Laarmann K, Janze N, Dittrich-Breiholz O, Kracht M, Goethe R. C/EBPβ is a transcriptional key regulator of IL-36α in murine macrophages. Biochim Biophys Acta 2015;1849:966-78. [PMID: 26066982 DOI: 10.1016/j.bbagrm.2015.06.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
514 Paskowitz DM, Greenberg KP, Yasumura D, Grimm D, Yang H, Duncan JL, Kay MA, Lavail MM, Flannery JG, Vollrath D. Rapid and Stable Knockdown of an Endogenous Gene in Retinal Pigment Epithelium. Human Gene Therapy 2007;18:871-80. [DOI: 10.1089/hum.2007.065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
515 Brown LJ, Longacre MJ, Hasan NM, Kendrick MA, Stoker SW, Macdonald MJ. Chronic reduction of the cytosolic or mitochondrial NAD(P)-malic enzyme does not affect insulin secretion in a rat insulinoma cell line. J Biol Chem 2009;284:35359-67. [PMID: 19858194 DOI: 10.1074/jbc.M109.040394] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
516 Melendez J, Sieiro D, Salgado D, Morin V, Dejardin MJ, Zhou C, Mullen AC, Marcelle C. TGFβ signalling acts as a molecular brake of myoblast fusion. Nat Commun 2021;12:749. [PMID: 33531476 DOI: 10.1038/s41467-020-20290-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
517 Bajan S, Hutvagner G. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells 2020;9:E137. [PMID: 31936122 DOI: 10.3390/cells9010137] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 39.5] [Reference Citation Analysis]
518 Li S, Hussain F, Unnithan GC, Dong S, UlAbdin Z, Gu S, Mathew LG, Fabrick JA, Ni X, Carrière Y, Tabashnik BE, Li X. A long non-coding RNA regulates cadherin transcription and susceptibility to Bt toxin Cry1Ac in pink bollworm, Pectinophora gossypiella. Pestic Biochem Physiol 2019;158:54-60. [PMID: 31378361 DOI: 10.1016/j.pestbp.2019.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
519 Zhang Y, Friedlander RM. Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther 2011;18:1139-49. [PMID: 22158031 DOI: 10.1038/gt.2011.170] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
520 Lundgren JG, Duan JJ. RNAi-Based Insecticidal Crops: Potential Effects on Nontarget Species. BioScience 2013;63:657-65. [DOI: 10.1525/bio.2013.63.8.8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 8.6] [Reference Citation Analysis]
521 Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TKH, Tang T. Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene 2014;538:217-27. [DOI: 10.1016/j.gene.2013.12.019] [Cited by in Crossref: 181] [Cited by in F6Publishing: 169] [Article Influence: 22.6] [Reference Citation Analysis]
522 Nemunaitis J, Rao DD, Liu SH, Brunicardi FC. Personalized cancer approach: using RNA interference technology. World J Surg 2011;35:1700-14. [PMID: 21557010 DOI: 10.1007/s00268-011-1100-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
523 Suter SR, Ball-Jones A, Mumbleau MM, Valenzuela R, Ibarra-Soza J, Owens H, Fisher AJ, Beal PA. Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications. Org Biomol Chem 2017;15:10029-36. [PMID: 29164215 DOI: 10.1039/c7ob02654d] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
524 Ahmed F, Raghava GP. Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS One 2011;6:e23443. [PMID: 21853133 DOI: 10.1371/journal.pone.0023443] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
525 Acosta J, Wang W, Feldser DM. Off and back-on again: a tumor suppressor's tale. Oncogene 2018;37:3058-69. [PMID: 29540833 DOI: 10.1038/s41388-018-0186-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
526 Zhang Y, Teng Y, Xiao W, Xu B, Zhao Y, Li W, Wu L. Identifying Cleaved and Noncleaved Targets of Small Interfering RNAs and MicroRNAs in Mammalian Cells by SpyCLIP. Mol Ther Nucleic Acids 2020;22:900-9. [PMID: 33251041 DOI: 10.1016/j.omtn.2020.10.009] [Reference Citation Analysis]
527 Rosario FJ, Sadovsky Y, Jansson T. Gene targeting in primary human trophoblasts. Placenta 2012;33:754-62. [PMID: 22831880 DOI: 10.1016/j.placenta.2012.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
528 Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 2016;538:114-7. [PMID: 27680702 DOI: 10.1038/nature19771] [Cited by in Crossref: 104] [Cited by in F6Publishing: 100] [Article Influence: 17.3] [Reference Citation Analysis]
529 Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol. 2009;27:549-555. [PMID: 19465925 DOI: 10.1038/nbt0709-671a] [Cited by in Crossref: 106] [Cited by in F6Publishing: 54] [Article Influence: 8.2] [Reference Citation Analysis]
530 Singh S, Narang AS, Mahato RI. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res. 2011;28:2996-3015. [PMID: 22033880 DOI: 10.1007/s11095-011-0608-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 11.1] [Reference Citation Analysis]
531 Shariat N, Ryther RC, Phillips JA 3rd, Robinson IC, Patton JG. Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference. Endocrinology 2008;149:580-6. [PMID: 18006625 DOI: 10.1210/en.2007-1360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
532 Sibley CR, Seow Y, Wood MJ. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther. 2010;18:466-476. [PMID: 20087319 DOI: 10.1038/mt.2009.306] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
533 Panwar V, McCallum B, Bakkeren G. Endogenous silencing of Puccinia triticina pathogenicity genes through in planta-expressed sequences leads to the suppression of rust diseases on wheat. Plant J 2013;73:521-32. [PMID: 23110316 DOI: 10.1111/tpj.12047] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 9.5] [Reference Citation Analysis]
534 Park HR, Oh R, Wagner P, Panganiban R, Lu Q. New Insights Into Cellular Stress Responses to Environmental Metal Toxicants. Int Rev Cell Mol Biol 2017;331:55-82. [PMID: 28325215 DOI: 10.1016/bs.ircmb.2016.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
535 Shao Y, Wu S, Chan CY, Klapper JR, Schneider E, Ding Y. A structural analysis of in vitro catalytic activities of hammerhead ribozymes. BMC Bioinformatics 2007;8:469. [PMID: 18053134 DOI: 10.1186/1471-2105-8-469] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
536 Hu R, Jia WY, Xu SF, Zhu ZW, Xiao Z, Yu SY, Li J. Xiaochaihutang Inhibits the Activation of Hepatic Stellate Cell Line T6 Through the Nrf2 Pathway. Front Pharmacol 2018;9:1516. [PMID: 30666206 DOI: 10.3389/fphar.2018.01516] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
537 Saetrom P, Heale BS, Snøve O Jr, Aagaard L, Alluin J, Rossi JJ. Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res 2007;35:2333-42. [PMID: 17389647 DOI: 10.1093/nar/gkm133] [Cited by in Crossref: 223] [Cited by in F6Publishing: 222] [Article Influence: 14.9] [Reference Citation Analysis]
538 Arora K, Rai AK, Devanna BN, Kumari B, Sharma TR. Functional validation of the Pi54 gene by knocking down its expression in a blast-resistant rice line using RNA interference and its effects on other traits. Funct Plant Biol 2018;45:1241-50. [PMID: 32291014 DOI: 10.1071/FP18083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
539 Welsbie DS, Mitchell KL, Jaskula-Ranga V, Sluch VM, Yang Z, Kim J, Buehler E, Patel A, Martin SE, Zhang PW, Ge Y, Duan Y, Fuller J, Kim BJ, Hamed E, Chamling X, Lei L, Fraser IDC, Ronai ZA, Berlinicke CA, Zack DJ. Enhanced Functional Genomic Screening Identifies Novel Mediators of Dual Leucine Zipper Kinase-Dependent Injury Signaling in Neurons. Neuron 2017;94:1142-1154.e6. [PMID: 28641113 DOI: 10.1016/j.neuron.2017.06.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 12.2] [Reference Citation Analysis]
540 Ibarra-Soza JM, Morris AA, Jayalath P, Peacock H, Conrad WE, Donald MB, Kurth MJ, Beal PA. 7-Substituted 8-aza-7-deazaadenosines for modification of the siRNA major groove. Org Biomol Chem 2012;10:6491-7. [PMID: 22766576 DOI: 10.1039/c2ob25647a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
541 Kim D, Kim J, Baek D. Global and local competition between exogenously introduced microRNAs and endogenously expressed microRNAs. Mol Cells 2014;37:412-7. [PMID: 24823356 DOI: 10.14348/molcells.2014.0100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
542 Suzuki K, Ishida T, Yamagishi M, Ahlenstiel C, Swaminathan S, Marks K, Murray D, McCartney EM, Beard MR, Alexander M. Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biol. 2011;8:1035-1046. [PMID: 21955498 DOI: 10.4161/rna.8.6.16264] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
543 Sullivan JM, Yau EH, Kolniak TA, Sheflin LG, Taggart RT, Abdelmaksoud HE. Variables and strategies in development of therapeutic post-transcriptional gene silencing agents. J Ophthalmol 2011;2011:531380. [PMID: 21785698 DOI: 10.1155/2011/531380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
544 Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009;1:142-51. [PMID: 20049714 DOI: 10.1002/emmm.200900023] [Cited by in Crossref: 190] [Cited by in F6Publishing: 163] [Article Influence: 15.8] [Reference Citation Analysis]
545 Parsel SM, Grandis JR, Thomas SM. Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 2016;35:3217-26. [PMID: 26592450 DOI: 10.1038/onc.2015.424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
546 Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov 2021;20:629-51. [PMID: 34145432 DOI: 10.1038/s41573-021-00219-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
547 Panwar V, McCallum B, Bakkeren G. Host-induced gene silencing of wheat leaf rust fungus Puccinia triticina pathogenicity genes mediated by the Barley stripe mosaic virus. Plant Mol Biol 2013;81:595-608. [PMID: 23417582 DOI: 10.1007/s11103-013-0022-7] [Cited by in Crossref: 121] [Cited by in F6Publishing: 91] [Article Influence: 13.4] [Reference Citation Analysis]
548 Saito T, Saetrom P. MicroRNAs--targeting and target prediction. N Biotechnol 2010;27:243-9. [PMID: 20219708 DOI: 10.1016/j.nbt.2010.02.016] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 6.6] [Reference Citation Analysis]
549 Lorenzo PI, Brendeford EM, Gilfillan S, Gavrilov AA, Leedsak M, Razin SV, Eskeland R, Sæther T, Gabrielsen OS. Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator. Genes Cancer 2011;2:805-17. [PMID: 22393465 DOI: 10.1177/1947601911428224] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
550 Andino LM, Takeda M, Kasahara H, Jakymiw A, Byrne BJ, Lewin AS. AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J Gene Med 2008;10:132-42. [PMID: 18064719 DOI: 10.1002/jgm.1131] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
551 Sepp-Lorenzino L, Ruddy M. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther. 2008;84:628-632. [PMID: 18800034 DOI: 10.1038/clpt.2008.174] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
552 Joseph TT, Osman R. Thermodynamic basis of selectivity in guide-target-mismatched RNA interference. Proteins 2012;80:1283-98. [PMID: 22275138 DOI: 10.1002/prot.24025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
553 Choi BM, Lee SH, An SM, Park DY, Lee GW, Noh GJ. The time-course and RNA interference of TNF-α, IL-6, and IL-1β expression on neuropathic pain induced by L5 spinal nerve transection in rats. Korean J Anesthesiol 2015;68:159-69. [PMID: 25844135 DOI: 10.4097/kjae.2015.68.2.159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
554 Boettcher M, McManus MT. Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Mol Cell 2015;58:575-85. [PMID: 26000843 DOI: 10.1016/j.molcel.2015.04.028] [Cited by in Crossref: 236] [Cited by in F6Publishing: 202] [Article Influence: 33.7] [Reference Citation Analysis]
555 Costa PM, Pedroso de Lima MC. MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) 2013;6:1195-220. [PMID: 24275848 DOI: 10.3390/ph6101195] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
556 LaPan P, Zhang J, Pan J, Hill A, Haney SA. Single cell cytometry of protein function in RNAi treated cells and in native populations. BMC Cell Biol 2008;9:43. [PMID: 18673568 DOI: 10.1186/1471-2121-9-43] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
557 McManus KJ, Barrett IJ, Nouhi Y, Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A. 2009;106:3276-3281. [PMID: 19218431 DOI: 10.1073/pnas.0813414106] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 7.2] [Reference Citation Analysis]
558 Herrera-Carrillo E, Harwig A, Liu YP, Berkhout B. Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity. RNA 2014;20:1410-8. [PMID: 25035295 DOI: 10.1261/rna.043950.113] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
559 Cho JS, Kim YC, Morrison SL. Inhibitors of MyD88-dependent proinflammatory cytokine production identified utilizing a novel RNA interference screening approach. PLoS One 2009;4:e7029. [PMID: 19753301 DOI: 10.1371/journal.pone.0007029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
560 Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-5. [PMID: 16873051 DOI: 10.1016/j.cell.2006.07.007] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 8.6] [Reference Citation Analysis]
561 Fennell M, Xiang Q, Hwang A, Chen C, Huang C, Chen C, Pelossof R, Garippa RJ. Impact of RNA-Guided Technologies for Target Identification and Deconvolution. J Biomol Screen 2014;19:1327-37. [DOI: 10.1177/1087057114548414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
562 Akimov IA, Kabilova TO, Vlassov VV, Chernolovskaya EL. Inhibition of human cancer-cell proliferation by long double-stranded RNAs. Oligonucleotides 2009;19:31-40. [PMID: 19125638 DOI: 10.1089/oli.2008.0151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
563 Kim DH, Rossi JJ. Overview of gene silencing by RNA interference. Curr Protoc Nucleic Acid Chem 2009;Chapter 16:Unit 16.1. [PMID: 19319858 DOI: 10.1002/0471142700.nc1601s36] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
564 Chien LT, Hartzell HC. Drosophila bestrophin-1 chloride current is dually regulated by calcium and cell volume. J Gen Physiol 2007;130:513-24. [PMID: 17968025 DOI: 10.1085/jgp.200709795] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
565 Kane NS, Vora M, Padgett RW, Li Y. bantam microRNA is a negative regulator of the Drosophila decapentaplegic pathway. Fly (Austin) 2018;12:105-17. [PMID: 30015555 DOI: 10.1080/19336934.2018.1499370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
566 Acunzo M, Romano G, Nigita G, Veneziano D, Fattore L, Laganà A, Zanesi N, Fadda P, Fassan M, Rizzotto L, Kladney R, Coppola V, Croce CM. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci U S A 2017;114:E4203-12. [PMID: 28484014 DOI: 10.1073/pnas.1620562114] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
567 Putzbach W, Gao QQ, Patel M, Haluck-Kangas A, Murmann AE, Peter ME. DISE: A Seed-Dependent RNAi Off-Target Effect That Kills Cancer Cells. Trends Cancer 2018;4:10-9. [PMID: 29413418 DOI: 10.1016/j.trecan.2017.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
568 Maguregui A, Abe H. Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability. Chembiochem 2020;21:1808-15. [PMID: 32181563 DOI: 10.1002/cbic.202000009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
569 de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007;6:443-53. [PMID: 17541417 DOI: 10.1038/nrd2310] [Cited by in Crossref: 868] [Cited by in F6Publishing: 821] [Article Influence: 57.9] [Reference Citation Analysis]
570 Franceschini A, Meier R, Casanova A, Kreibich S, Daga N, Andritschke D, Dilling S, Rämö P, Emmenlauer M, Kaufmann A, Conde-Álvarez R, Low SH, Pelkmans L, Helenius A, Hardt WD, Dehio C, von Mering C. Specific inhibition of diverse pathogens in human cells by synthetic microRNA-like oligonucleotides inferred from RNAi screens. Proc Natl Acad Sci U S A 2014;111:4548-53. [PMID: 24616511 DOI: 10.1073/pnas.1402353111] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
571 Li CH, Chen Y. Targeting long non-coding RNAs in cancers: Progress and prospects. The International Journal of Biochemistry & Cell Biology 2013;45:1895-910. [DOI: 10.1016/j.biocel.2013.05.030] [Cited by in Crossref: 318] [Cited by in F6Publishing: 324] [Article Influence: 35.3] [Reference Citation Analysis]
572 Xu Y, Mirmalek-Sani SH, Lin F, Zhang J, Oreffo RO. Adipocyte differentiation induced using nonspecific siRNA controls in cultured human mesenchymal stem cells. RNA 2007;13:1179-83. [PMID: 17556710 DOI: 10.1261/rna.527207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
573 Okamura K, Robine N, Liu Y, Liu Q, Lai EC. R2D2 organizes small regulatory RNA pathways in Drosophila. Mol Cell Biol 2011;31:884-96. [PMID: 21135122 DOI: 10.1128/MCB.01141-10] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
574 Farra R, Dapas B, Pozzato G, Scaggiante B, Agostini F, Zennaro C, Grassi M, Rosso N, Giansante C, Fiotti N. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells. Dig Liver Dis. 2011;43:1006-1014. [PMID: 21831731 DOI: 10.1016/j.dld.2011.07.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
575 Ulusoy A, Kirik D. Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinson’s disease. Therapeutic Delivery 2011;2:37-50. [DOI: 10.4155/tde.10.95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
576 Gore KR, Nawale GN, Harikrishna S, Chittoor VG, Pandey SK, Höbartner C, Patankar S, Pradeepkumar PI. Synthesis, gene silencing, and molecular modeling studies of 4'-C-aminomethyl-2'-O-methyl modified small interfering RNAs. J Org Chem 2012;77:3233-45. [PMID: 22372696 DOI: 10.1021/jo202666m] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
577 Conrad C, Gerlich DW. Automated microscopy for high-content RNAi screening. J Cell Biol 2010;188:453-61. [PMID: 20176920 DOI: 10.1083/jcb.200910105] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 9.4] [Reference Citation Analysis]
578 Haley B, Foys B, Levine M. Vectors and parameters that enhance the efficacy of RNAi-mediated gene disruption in transgenic Drosophila. Proc Natl Acad Sci U S A 2010;107:11435-40. [PMID: 20534445 DOI: 10.1073/pnas.1006689107] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
579 Matoba R, Niwa H, Masui S, Ohtsuka S, Carter MG, Sharov AA, Ko MS. Dissecting Oct3/4-regulated gene networks in embryonic stem cells by expression profiling. PLoS One 2006;1:e26. [PMID: 17183653 DOI: 10.1371/journal.pone.0000026] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 8.1] [Reference Citation Analysis]
580 Diosa-Toro M, Urcuqui-Inchima S, Smit JM. Arthropod-borne flaviviruses and RNA interference: seeking new approaches for antiviral therapy. Adv Virus Res 2013;85:91-111. [PMID: 23439025 DOI: 10.1016/B978-0-12-408116-1.00004-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
581 Schultz N, Marenstein DR, De Angelis DA, Wang WQ, Nelander S, Jacobsen A, Marks DS, Massagué J, Sander C. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence 2011;2:3. [PMID: 21401928 DOI: 10.1186/1758-907X-2-3] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
582 Vankoningsloo S, de Longueville F, Evrard S, Rahier P, Houbion A, Fattaccioli A, Gastellier M, Remacle J, Raes M, Renard P, Arnould T. Gene expression silencing with 'specific' small interfering RNA goes beyond specificity - a study of key parameters to take into account in the onset of small interfering RNA off-target effects. FEBS J 2008;275:2738-53. [PMID: 18422646 DOI: 10.1111/j.1742-4658.2008.06415.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
583 Valenzuela RA, Suter SR, Ball-Jones AA, Ibarra-Soza JM, Zheng Y, Beal PA. Base modification strategies to modulate immune stimulation by an siRNA. Chembiochem 2015;16:262-7. [PMID: 25487859 DOI: 10.1002/cbic.201402551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
584 Perwitasari O, Bakre A, Tompkins SM, Tripp RA. siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) 2013;6:124-60. [PMID: 24275945 DOI: 10.3390/ph6020124] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
585 Moon SH, Jenkins CM, Mancuso DJ, Turk J, Gross RW. Smooth muscle cell arachidonic acid release, migration, and proliferation are markedly attenuated in mice null for calcium-independent phospholipase A2beta. J Biol Chem 2008;283:33975-87. [PMID: 18927078 DOI: 10.1074/jbc.M805817200] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
586 Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res 2008;36:7100-9. [PMID: 18988625 DOI: 10.1093/nar/gkn902] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 6.7] [Reference Citation Analysis]
587 Godec J, Cowley GS, Barnitz RA, Alkan O, Root DE, Sharpe AH, Haining WN. Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation. Proc Natl Acad Sci U S A 2015;112:512-7. [PMID: 25548173 DOI: 10.1073/pnas.1413291112] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
588 Lee HS, Seok H, Lee DH, Ham J, Lee W, Youm EM, Yoo JS, Lee YS, Jang ES, Chi SW. Abasic pivot substitution harnesses target specificity of RNA interference. Nat Commun 2015;6:10154. [PMID: 26679372 DOI: 10.1038/ncomms10154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
589 Lennox KA, Behlke MA. Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents. Methods Mol Biol 2020;2115:23-55. [PMID: 32006393 DOI: 10.1007/978-1-0716-0290-4_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
590 Zhong R, Kim J, Kim HS, Kim M, Lum L, Levine B, Xiao G, White MA, Xie Y. Computational detection and suppression of sequence-specific off-target phenotypes from whole genome RNAi screens. Nucleic Acids Res 2014;42:8214-22. [PMID: 24972830 DOI: 10.1093/nar/gku306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
591 Tomaru Y, Nakanishi M, Miura H, Kimura Y, Ohkawa H, Ohta Y, Hayashizaki Y, Suzuki M. Identification of an inter-transcription factor regulatory network in human hepatoma cells by Matrix RNAi. Nucleic Acids Res 2009;37:1049-60. [PMID: 19129217 DOI: 10.1093/nar/gkn1028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
592 Borel F, Kay MA, Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 2014;22:692-701. [PMID: 24352214 DOI: 10.1038/mt.2013.285] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
593 Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007;59:164-182. [PMID: 17481774 DOI: 10.1016/j.addr.2007.03.010] [Cited by in Crossref: 156] [Cited by in F6Publishing: 150] [Article Influence: 10.4] [Reference Citation Analysis]
594 Guzman-Villanueva D, El-Sherbiny IM, Herrera-Ruiz D, Vlassov AV, Smyth HD. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications. J Pharm Sci 2012;101:4046-66. [PMID: 22927140 DOI: 10.1002/jps.23300] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
595 Younis HS, Templin M, Whitely LO, Kornbrust D, Kim T, Henry SP. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. A Comprehensive Guide to Toxicology in Preclinical Drug Development. Elsevier; 2013. pp. 647-64. [DOI: 10.1016/b978-0-12-387815-1.00026-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]